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ABSTRACT 
 
LISA MADONIA LOMAS:  Sex Differences in Opioid Antinociception in Acute and 
Chronic pain models: The Involvement of the N-methyl-D-Aspartate System 
(Under the direction of Mitchell J. Picker) 
 
There is ample evidence that males and females differ markedly in their sensitivity to 
the antinociceptive effects of opioids that are active at µ and κ receptor. The following 
studies examined the role of the NMDA receptor system in modulating sexually dimorphic 
opioid antinociception using acute (hot-plate and warm water tail-withdrawal) and persistent 
(temporal summation and capsaicin) models of nociception.   
Experiment 1 focused on the development of a behavioral procedure to induce 
temporal summation in rats and determined the sensitivity of this behavior temporal 
summation in rats to various parametric manipulations, sex, modulation by the NMDA 
receptor system, and sensitivity to reversal by opioids. Males displayed slightly higher levels 
of temporal summation than females. NMDA antagonists attenuated the level of temporal 
summation in both sexes. There were no sex differences in µ and κ opioids effectiveness in 
this procedure.  
Experiment 2 evaluated sex differences in the antihyperalgesic actions of selected κ 
and mixed-action opioids in a persistent pain model and examined the role of the NMDA 
system to modulate these effects in a sexually-dimorphic manner in rats. In general, κ opioids 
were more potent in males when administered both peripherally and systemically. Sex 
differences were not observed with the mixed-action opioids. The NMDA antagonist 
 iii
dextromethorphan attenuated κ opioid induced antihyperalgesia in both sexes. In contrast to 
the findings in acute pain models, antagonism at the NMDA receptor site did not modulate 
the effects of κ opioids in a sexually-dimorphic manner.  
Experiment 3 examined sex differences in the influence of the NMDA antagonist 
dextromethorphan on µ opioid antihyperalgesia in the capsaicin persistent pain model and 
two acute nociceptive assays.  Dextromethorphan enhanced the antihyperalgesic effect of 
morphine in males but not females in the capsaicin assay.  Enhancement of antinociception 
was seen in both sexes in the acute pain models, with greater magnitude in males. These 
findings demonstrate a sexually dimorphic interaction between the NMDA antagonist 
dextromethorphan and morphine in a persistent pain model that can be quantitatively 
distinguished from those observed in acute pain models. 
In summary these experiments demonstrate the importance of pain model in 
investigations of sex differences in opioid analgesia and its possible mechanisms.  
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
There is now an abundance of evidence indicating differences in the sensitivity of 
males and females to µ and κ opioid analgesics, as well as sex differences in the effects of 
various mixed-action analgesics (Gear et al., 1996, 1999; Sarton et al, 1999). The root of 
research in sex differences in opioid analgesia lies in the finding of an ineffectiveness of 
clinically employed doses of morphine in almost a third of post-surgical pain patients 
(Lasagna and Beecher, 1954). This finding prompted investigation into the reasons behind 
this lack of opioid effectiveness in such a large group of patients. While there is an extensive 
list of factors that could account for individual differences in opioid effectiveness, such as the 
patients’ age, opioid history and willingness to report pain     (Burns et al 1989; Mercandante 
et al 1997; Miaskowski and Levine 1999); a primary physiological factor appears to be the 
sex of the individual.  
Clinically, males and females have been shown to differ in the amount of morphine 
required to control post-surgical pain, as well as differing in the level and duration of 
analgesia produced by opioids (Gear et al., 1996; Sarton et al., 2000; Mogil et al., 2003).   As 
observed in humans, marked sex differences in opioid antinociception have been found in 
many different species (Cicero et al., 1996; Kest et al., 1999; Negus and Mello 1999; Craft 
and Bernal, 2000; Mogil et al., 2000; Craft, 2003). For example, the µ opioid morphine has 
been shown to be more potent in producing antinociception in male rodents  than in their 
female counterparts, and this effect has been observed across a variety of nociceptive stimuli 
and rodent strains (Cicero et al., 1996, 1997; Kest et al., 1999; Terner et al., 2003).  A 
number of mechanisms have been proposed to account for these sex differences; however, it 
is now known that sex differences in opioid antinociception are not a consequence of sex-
specific opioid binding affinity, G-protein stimulation, or receptor density (Messing et al., 
1980; Kepler et al., 1991; Candido et al., 1992; Selly et al., 2003). Pharmacokinetic factors 
have also been ruled out, as blood and brain concentrations of morphine are similar in males 
and females after systemic injection (Cicero et al., 1997).  
Although the activational and organizational effects of gonadal hormones are key 
factors in modulating sex differences in opioid antinociception, it is also clear that other 
factors play critical roles (Cicero et al., 2002). Recent in vivo and in vitro studies, for 
example, suggest that the NMDA receptor system may be intricately involved in this 
interaction. Arguably, the strongest indication of a relationship between these two systems 
comes from morphological evidence indicating co-localization of NMDA and opioid 
receptors in the central nervous system.  Specifically, NMDA and opioid receptors have been 
identified in the spinal cord dorsal horn and periaqueductal grey(Commons et al., 1999; 
Aicher et al., 2002). The periaqueductal gray (PAG), and its projections to the rostral 
ventromedial medulla (RVM) and spinal cord, makeup the primary circuit for opioid 
analgesia (Basbaum and Fields, 1984). In vivo studies support these observations, as NMDA 
antagonists enhance the antinociceptive effects of µ opioids in various acute pain models 
(Allen and Dykstra, 2001; Redwine and Trujillo, 2003; Nemanni et al., 2004), and minimize 
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the development of both µ opioid tolerance and dependence (Truijillo and Akil, 1991; 
Kolesnikov and Pasternak, 1999).   
Recent studies also suggest that the interaction between the NMDA and opioid 
systems may be sexually dimorphic. For example, stress-induced antinociception has been 
shown to be attenuated by NMDA antagonists in male but not female mice. In females, this 
effect is mediated by the gonadal hormones, as NMDA antagonists reverse stress-induced 
antinociception in ovariectomized females  (Mogil and Belknap, 1997). Perhaps more 
importantly, NMDA antagonists selectively attenuate the effect of κ opioid antinociception in 
males (Suacier and Kavaliers, 1994; Kavaliers and Choleris, 1997) and in ovariectomized 
females (Sternberg et al., 2004).  
New findings indicate that µ opioid antinociception can be dramatically enhanced by 
NMDA antagonists, and this effect also appears to be sex-specific (Holtman et al., 2003; 
Nemmani et al, 2004). Such findings suggest further that there are fundamental differences 
between males and females in the extent to which the NMDA system can modulate opioid 
antinociception. This sexually dimorphic interaction is not only observed in behavioral 
measures of nociception; NMDA antagonists also reduce morphine induced c-Fos expression 
in a sexually dimorphic manner (D’Souza et al., 1999). It is likely the sex differences 
observed in opioid antinociception are due, in part, to a sexual differentiation in the NMDA 
system and how it this system modulates the opioid system.  
Sex difference in opioid antinociception and its relationship to the NMDA system 
have been examined in a limited set of conditions and nociceptive models. Pain models in 
animals are an important means by which the mechanisms and maintenance of pain can be 
understood (Aloisi et al, 1995). Analyses of these models have revealed that the mechanisms 
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underlying nociception are dependent upon a number of factors, including the duration of the 
nociceptive stimulus (McLaughlin and Dewey, 1994).  Behavioral models of pain can be 
classified by the duration of nociceptive stimulus as either phasic (acute) tests such as the tail 
flick or tail-withdrawal assay or tonic tests (more long lasting; persistent). These models vary 
in transmission of nociceptive information as well as nociceptive response (Le Bars et al, 
2001). In acute tests there is typically the application of a brief noxious stimulus followed by 
a withdrawal behavior by the animal (Mogil et al., 2000). Persistent models, which seek to 
model more long term pain, often result in hyperalgesia, inflammation and/or tissue damage 
(Le Bars et al, 2001). Moreover, in acute pain models, opioids produce effects via spinal and 
supraspinal sites,  alternatively in some persistent pain models opioids are effective when 
administered peripherally at the site of injury, which is not true in acute models (Yaksh, 
1997).  While there is limited research on sex differences in opioid antinociception in 
persistent models of pain, there is some indication that females have a greater nociceptive 
response in these assays. For example, in the formalin assay which is a model of persistent 
pain, injections of formalin produced greater hindpaw licking in females rats compared to 
males. Male rats are also less sensitive to the hyperalgesic effects of capsaicin compared to 
their female counterparts in the capsaicin model of persistent pain (Aloisi et al., 1994; 
Gaumond et al., 2002; Barrett et al., 2003). Recent studies indicate, at least with µ opioids, 
there may not be large sex differences in opioid antinociception in the capsaicin persistent 
model of pain (Barrett et al., 2003). The issue of chronicity of the pain model is critical in 
that these models vary on so many dimensions. Evaluation in both persistent and acute 
models of pain is necessary in order to have a full understanding of sex differences in opioid 
antinociception. 
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Central sensitization is a phenomenon thought to be an integral factor in the 
development of persistent pain (Coderre, 1993; Woolf, 1996; Li et al., 1999). Central 
sensitization is most commonly described as an increased excitability of central wide 
dynamic range neurons in the spinal cord (Eide, 2000). This event is a reaction to increased 
activity at nociceptors, such as from injury or inflammation (Woolf, 1996). This central 
activity may play a role in many chronic pain conditions and is specific to persistent pain; it 
is typically not a factor in acute pain. One proposed factor underlying central sensitization is 
wind-up, in which the repeated stimulation of the C primary nociceptive afferents induces 
hyperactivity of dorsal horn neurons (Mendell and Wall, 1965; Woolf, 1996). The behavioral 
correlate of this phenomenon, as seen in humans, is temporal summation of pain (Ren, 1994; 
Li et al., 1999), or the increase in pain following repeated presentation of a nociceptive 
stimulus. This short-lasting change in nociceptive sensitivity has been employed in humans 
to examine factors that influence the central processing of pain and the mechanisms 
underlying some chronic pain conditions. Interestingly the NMDA receptor system appears 
to play in a role in the development of central sensitization and wind-up as NMDA 
antagonists have been shown to inhibit wind-up in dorsal horn neurons (Dickenson and 
Sullivan, 1987). The purpose of Experiment 1 was to provide a detailed evaluation of sex 
differences in the sensitivity of opioids in a model of persistent pain by developing a model 
of temporal summation of pain in rats. Male and female rats were evaluated for nociceptive 
response in a novel behavioral model of temporal summation (i.e., decrease tail-withdrawal 
latency following repeated presentations of a nociceptive thermal stimulus). Sensitivity to 
various parametric manipulations, sex, modulation by the NMDA receptor system, and 
sensitivity to reversal by opioids were examined. 
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 Sex differences in the potency of the antinociceptive effects of κ opioids have been 
reported in acute pain models and when opioid activity is centrally mediated. In acute 
models, the nociceptive stimulus activates large Aδ nociceptive fibers. In contrast,  
nociception in persistant pain models is associated with slower, C nociceptive fiber activation 
as well as tissue damage and inflamation. The distinction between acute and persistent pain 
models is critical to the the study of sex differences in opioid analgesia as  these models can 
be differentially modulated by the NMDA system. Sex differences in antinociception may be 
dependent upon the opioid system’s interaction with the type/duration of nociception elcited 
(Barrett et al., 2003; Lomas et al.,2007).  Recent studies support this contention as the 
magnitude of sex differences in opioid antinociception has been demonstrated to be  larger in 
models of acute than chronic pain in a study on µ opioids (e.g., Barrett et al., 2003). Given 
the possible importance of pain model in determining antinociceptive responses and role of 
the NMDA receptor system, both experiment 2 and 3 utilized the non-NMDA mediated 
capsaicin model of persistent pain. In experiment 2 a capsaicin model of persistent pain was 
used to compare κ opioid-induced antihyperalgesia in intact F344 male and female rats. 
Various κ opioids and mixed action opioids were tested in this 45oC tail-withdrawal assay 
measuring hyperalgesia.  There is evidence that opioids can produce their effects not only by 
central receptor action, but also by peripheral receptors in models of inflammation, with 
select opioids having greater potency peripherally (Ko et al., 1998; Ko et al., 2000). The 
capsaicin model was used to identify potential sex differences in κ opioid effectiveness both 
peripherally and centrally. Additional tests were conducted to examine the effect of κ 
opioid/NMDA antagonist combinations on antihyperalgesia in this persistent model of pain. 
 There is a large body of evidence suggesting the NMDA system modulation of the 
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opioid effects. NMDA antagonists have been shown to inhibit the development of opioid 
tolerance, dependence and sensitization (Mao, 1999; Popik, 2000; Trujillo, 2000). NMDA 
antagonist enhancement of µ opioid antinociception has been observed in a number of 
species (Allen and Dykstra, 2001; Caruso, 2000; Holtman et al, 2003; Redwine and Trujillo, 
2003). To date, most evidence demonstrating that NMDA antagonists enhance opioid 
antinociception, as well examination of sex differences in this effect, have been obtained in 
models of acute pain. In Experiment 3, a capsaicin model of persistent pain was used to 
examine sex differences in NMDA modulation of µ opioid-induced antihyperalgesia. At the 
supraspinal level, NMDA receptors are found in the hippocampus, thalamus and brainstem 
(Roth et al., 1996; Suzuki et al., 1996), whereas, at the spinal level, NMDA receptors have 
been primarily identified in the dorsal horn (Petralia et al., 1994; Tolle et al., 1995). Opioid 
receptor density is also relatively high at these sites. Therefore NMDA/µ opioid interactions 
were also evaluated using acute nociceptive assays with both a nociceptive response that is 
primarily supraspinally mediated (hot-plate: hind paw lift or escape) and one that is primarily 
spinally mediated (warm water tail-withdrawal) (Le Bars, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 7
 CHAPTER 2 
     EXPERIMENT 1: BEHAVIORAL ASSESMENT OF TEMPORAL SUMMATION 
IN THE RAT: SENSITIVITY TO SEX, GONADAL HORMONE DEPLETION, 
OPIOIDS AND MODULATION BY NMDA RECEPTOR ANTAGONISTS 
 
Introduction 
Several lines of evidence suggest that hyperalgesia, allodynia and some chronic pain 
conditions may be due, in part, to the enhanced excitability of central wide dynamic range 
neurons in the spinal cord. This excitability can be induced by inflammation, tissue damage 
(central sensitization) and artificially by repeated stimulation of dorsal horn neurons, a 
phenomenon known as wind-up (Mendell and Wall 1965; Coderre et al. 1993; Woolf 1996). 
Wind-up frequently occurs following repetitive heat pulses at intervals of 3 seconds or less 
and is associated with a gradual increase in pain perception mediated by activity in the 
central nervous system  (Price 1977; Fillingim et al. 1998). A behavioral manifestation of this 
central excitability is temporal summation (Ren 1994; Li et al. 1999), which in humans is 
characterized by an increase in pain sensitivity following repeated presentations of a 
nociceptive stimulus. This increase in pain sensitivity typically outlasts exposure to the 
nociceptive stimulus, with painful after-sensations reported as long as 15 and 120 secs 
following the termination of the nociceptive stimulus (Staud et al. 2001, 2003).   
 Temporal summation of pain has been shown to be sensitive to organismic factors, 
such as health status, sex and age. For example, in some chronic pain patients and the elderly 
there is heightened level of temporal summation (Maxiner et al. 1998; Edwards and Fillingim 
2001; Staud et al. 2001), whereas in healthy young subjects temporal summation of pain is 
inversely correlated with perceptions of general health (Edwards and Fillingim 2001). 
Moreover, females display greater levels of temporal summation of pain and unpleasantness 
ratings than males with these effects evident for both thermal and mechanical nociceptive 
stimuli (Fillingim et al. 1998; Sarlani and Greenspan 2002; Sarlani et al. 2004). That females 
also display lower pain thresholds and are more likely to develop certain chronic pain 
conditions (Unruh 1996), suggests that temporal summation of pain may represent a model to 
investigate the factors involved in the development of chronic pain. 
 There is a growing body of evidence indicating that activation of the N-methly-D-
aspartate (NMDA) system is involved in some chronic pain conditions, thus it is not 
surprising that this system has also been linked to the development of temporal summation of 
pain. For example, NMDA receptor antagonists attenuate temporal summation of pain in 
humans, with the magnitude of this effect varying markedly across NMDA antagonists 
(Arendt-Nielsen et al. 1994; 1995; Price et al. 1994). Likewise, NMDA antagonists can be 
effective at reducing evoked pain in individuals with neuropathic pain (Eide et al. 1994; 
Mathison et al. 1995) and may hold promise as a treatment for certain chronic pain 
conditions (Eide 2000).  
 Opioids have been reported to be effective in reducing the development of temporal 
summation in humans (Price, 1985). Although sex differences in this effect have not been 
systematically examined in the temporal summation procedure (for an exception see 
Fillingim et al. 2004), sex differences in opioid sensitivity have been observed in the post-
surgical setting (Gordon et al. 1995; Fillingim and Gear, 2004). This effect appears to be 
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least evident with high efficacy opioids (e.g., morphine) and most evident with less 
efficacious opioids (e.g., butorphanol). In non-humans, sex differences have been 
consistently observed with low efficacy opioids in procedures that induce acute (e.g., Cook et 
al. 2000; Craft and Bernal 2001) but not chronic nociception (Barrett et al. 2003). As in the 
development of temporal summation, the NMDA system appears to play a critical role in the 
development of chronic nociception (Przewlocki and Przewlocki 2001). Consequently, the 
use of the temporal summation procedure should provide important information concerning 
sex differences in opioid sensitivity under chronic pain conditions. 
 The purpose of this investigation was to determine if repeated presentations of a 
thermal nociceptive stimulus produces systematic increases in nociceptive sensitivity in rats. 
Such an effect would be functionally equivalent to temporal summation of pain in humans, 
and would thus allow for the assessment of the mechanisms underlying central sensitization 
and the factors that influence some chronic pain conditions. In this investigation, we focused 
on the sensitivity of temporal summation in rats to sex, gonadal hormone depletion, 
modulation by non-competitive NMDA receptor antagonists and reversal by opioids active at 
µ and κ receptors.  
 
Methods 
Animals 
Gonadally intact and gonadectomized (GDX) male and female F344 rats were obtained from 
Charles River Suppliers (Raleigh, N.C., USA). F344 rats were selected for study as this strain 
was shown to display marked differences in both nociceptive and opioid sensitivity (Cook et 
al. 2000; Barrett et al. 2003; Terner et al. 2003). All testing occurred when the rats were 
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between 3 and 6 months of age. Rats were housed individually in a colony maintained on a 
12-h light/ dark cycle and had unlimited access to food and water. Animals used in this study 
were cared for in accordance with the guidelines of the Institutional Animal Care and Use 
Committee of the University of North Carolina, and the “Guidelines for the Care and Use of 
Mammals in Neuroscience and Behavioral Research” (Committee on Guidelines for the Use 
of Animals in Neuroscience and Behavioral Research, National Research Council National 
Academy Press, 2003). 
 
Temporal summation procedure 
After a habituation procedure (see Terner et al. 2003), rats were placed in restraint tubes, the 
distal 7 cm of the tail immersed in warm water, and the time recorded to tail-withdrawal 
(baseline tail-withdrawal latency). For all baseline tests, a 15 sec cut-off time was imposed to 
prevent tissue damage. Approximately 2 mins later, the temporal summation testing 
procedure was initiated. This procedure consisted of repeatedly placing the rat’s tail in the 
warm water for 1.0-3.0 secs. After a set number of presentations of the nociceptive stimulus, 
with each presentation separated by a brief interval, tail-withdrawal latency was again 
recorded with the 15 sec cut-off still imposed.  
 
Parametric analyses 
Extensive parametric testing was required, as in humans temporal summation of pain is 
highly dependent on the inter-nociceptive stimulus intervals, nociceptive stimulus intensities 
and the frequency of nociceptive stimulus presentations (Price 1977; Fillingim et al. 1998; 
Maixner et al. 1998). Five parameters of the procedure used to assess temporal summation 
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magnitude were altered, including (1) repetitions of the nociceptive stimulus  (number of 
times the tail was placed in warm water), (2) the duration of the nociceptive stimulus (length 
of time in which the tail was placed  in warm water), (3) interval between nociceptive 
stimulus presentations (time between when the tail was removed from the warm water and 
then placed back in warm water), (4) intensity of the nociceptive stimulus (water 
temperature), and (5) test time (time between the final presentation of the nociceptive 
stimulus and when the test for temporal summation was conducted). Each group of animals 
(n=7-8 males/females) was generally used for 8-10 tests (one parametric manipulation), with 
each test separated by a minimum of 48 hrs.  
Data from studies using human subjects indicated that the optimal time between 
nociceptive stimulus presentations is 3.0 secs (Price et al. 1977), therefore the majority of 
parametric tests were conducted using this time interval (inter-stimulus interval, ISI). 
Preliminary tests also indicated that after approximately eight presentations of the 
nociceptive stimulus, the rats failed to leave their tails in the water for a stimulus duration of 
3.0 secs, thus limiting both the duration of exposure to the nociceptive stimulus and the 
frequency at which it could be presented in this model. Due to these constraints, much of the 
testing was conducting using eight presentations of the nociceptive stimulus, a 3.0-s 
nociceptive stimulus and a 3.0-s ISI. The specific parameters used and testing conditions are 
indicated in Table 1. 
 
Drug testing: NMDA antagonists and Opioids   
For drug testing, the stimulus presentation number was set at 8 with a 1.0-sec exposure to the 
warm water stimulus, a 3.0-sec ISI, and tests of temporal summation conducted 3-secs after 
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the final nociceptive stimulus presentation. All drug tests were conducted following a 30 min 
pretreatment interval with an i.p. administration of saline or selected doses of the following 
drugs: the NMDA antagonists ketamine (3.0-30 mg/kg), dizocilpine (0.03-0.1 mg/kg), and 
dextromethorphan (10-30 mg/kg), the µ opioids morphine (3.0-10 mg/kg) and buprenorphine  
(0.3-3.0 mg/kg), the mixed-action opioid butorphanol (3.0-30 mg/kg) and the κ opioid  
spiradoline (10-30 mg/kg). All drug doses were tested at 51ºC water, whereas the highest 
doses of the NMDA antagonists were also tested at 49ºC water. These parameters were 
selected as they produced both low (49ºC) and high (51ºC) levels of temporal summation. 
For all tests, each group of rats (n=6-8) was tested with a single drug, and at least 6 days 
separated each test.  
 
Data analysis 
Latencies to tail-withdrawal following the temporal summation procedure were converted to 
percent of the baseline tail-withdrawal latency using the following equation: % of Baseline = 
[((observed – baseline) baseline x 100) + 100]. For this analysis, 100% of baseline indicated 
that the tail-withdrawal latency following the temporal summation procedure was equal to 
baseline latency prior to initiation of the temporal summation procedure. Less than 100% of 
baseline represented a decrease in tail-withdrawal latency, or hyperalgesia. Mixed model 
analyses of variance (ANOVA) were conducted to determine the influence of the various 
parameter manipulations and sex. Baseline tail-withdrawal latencies were also analyzed 
using a repeated measures ANOVA with sex as the between groups factor and temperature as 
the repeated measures factor. 
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For determining the antinociceptive effect of drugs, baseline tail-withdrawal latencies 
following administration of drug were converted to a percentage of antinociception using the 
following equation: % antinociceptive effect = [(observed drug baseline – saline baseline)/ 
(15s-saline baseline)] x 100. To determine the antihyperalgesic effective of drugs, tail-
withdrawal latencies following administration of drug were converted to a percent 
antihyperalgesic effect using the following equation: % antihyperalgesia [(temporal 
summation level with drug – saline temporal summation level) / (saline temporal summation 
baseline – saline temporal summation level)] x 100.  For NMDA antagonists an ANOVA 
was conducted with sex, drug and temperature as factors to determine their influence on 
temporal summation. For all tests, the α level was set at 0.05. For opioids, the dose of each 
drug required to produce a 50% (ED50) maximal antinociceptive effect, 50% (ED50) 
antihyperalgesic effect (the dose of drug that increased temporal summation tail-withdrawal 
latency by 50%) and the 95% confidence limits were derived mathematically (least-squares 
method) using log linear interpolation with at least three doses on the ascending limb of the 
dose–effect curve. Relative potency estimates were calculated in a manner described by 
Tallarida and Murray (1987), in which the relative potency of each opioid tested in male rats 
was compared to their female counterparts. Differences between sexes in the relative potency 
of opioids were considered to be significant if the 95% confidence interval did not overlap 
1.0. 
 
Drugs 
The following drugs were examined: ketamine HCl (Abbott Laboratories, North Chicago, 
IL), dizocilpine hydrogen maleate, dextromethorphan hydrobromide monohydrate, 
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spiradoline mesylate, butorphanol tartrate (all purchased from Sigma-Aldrich, St Louis MO), 
morphine sulfate, and buprenorphine HCl (both provided by the National Institute on Drug 
Abuse, Bethesda, MD). All drugs were dissolved in distilled water and administered i.p. in an 
injection volume of 0.5–1.0 ml/kg. Doses of drugs are expressed in terms of salts. 
 
Results 
Baseline latencies 
Prior to testing in the temporal summation procedure, baseline tail-withdrawal 
latencies were recorded across a range of nociceptive stimulus intensities (water temperature) 
in the warm water tail-withdrawal procedure. In both male and female rats baseline tail-
withdrawal latencies decreased with increases in the nociceptive stimulus intensity (Table 1). 
At almost all intensities tested, tail-withdrawal latencies were longer in males than their 
female counterparts. Analyses confirmed a main effect for both nociceptive stimulus 
intensity (F5,60=34.8, P<0.05) and sex (F1,12=8.96, P<0.05).  
 
Temporal Summation: Nociceptive stimulus intensity  
Figure 1 shows the level of temporal summation in males and females at nociceptive 
stimulus intensities ranging from 45 to 52ºC. Data illustrated in this and other figures reflect 
a representative subset of the data: in almost all instances, parametric tests were conducted 
using various nociceptive stimulus presentations, ISIs, nociceptive stimulus durations and 
nociceptive stimulus intensities (A complete list of all testing conditions are shown in Table 
1.)  Data portrayed in this and other figures are generally consistent with the findings 
obtained across the parameters tested. Unless otherwise noted (see specifics of each panel 
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and each figure), data displayed in these panels, as well as for other figures, are for tests 
conducted using 51ºC water, 8 nociceptive stimulus presentations, 3.0 sec ISI, 3.0 sec 
duration of the nociceptive stimulus, with tests for temporal summation conducted 3.0 secs 
following the final presentation of the nociceptive stimulus. In this figure, increases in the 
level of temporal summation are represented by a decrease in the percentage of baseline 
latency. In both males and females, the level of temporal summation (i.e., hyperalgesia) 
increased with increases in the nociceptive stimulus intensity. In general, the magnitude of 
this effect was larger in males than females. At the lowest nociceptive stimulus intensity 
tested (45ºC), there was little evidence of temporal summation, whereas the largest effects 
were obtained at the higher nociceptive stimulus intensities (49-52ºC). Analyses of these data 
confirmed a main effect for nociceptive stimulus intensity (F5,60=41.3, P<0.05), a main effect 
for sex (F1,12=11.1, P<0.05) and a nociceptive stimulus intensity x sex interaction (F5,60=2.84, 
P<0.05).  
 Comparisons were also made on the basis of absolute tail-withdrawal latencies in 
males and females (data not shown). Although this analysis identified a main effect for 
nociceptive stimulus intensity (F5,60=89.3, P<0.05), there was no main effect for sex or a 
nociceptive stimulus intensity x sex interaction. Thus, sex differences in temporal summation 
were apparent when the data were expressed as a percent of baseline but not as absolute 
latencies. Such finding suggested that sex differences in baseline latencies may contribute to 
the differential development of temporal summation and thus the interpretation of all 
parametric manipulations and drug tests (see below). 
Temporal Summation: Nociceptive presentation number, inter-stimulus interval (ISI) 
and nociceptive stimulus duration The level of temporal summation varied as a function of 
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the number of presentations of the nociceptive stimulus with temporal summation evident at 
each presentation number (Fig. 2A). The smallest effect was observed when the nociceptive 
stimulus was presented a single time and the largest at presentations of 8 and 12. Similar 
findings were obtained at the other nociceptive stimulus intensities tested as well as at the 
other testing parameters. Across the different presentation numbers and nociceptive stimulus 
intensities tested, the magnitude of temporal summation was generally greater in males than 
females. Analyses across all tests confirmed a main effect for number of stimulus 
presentations (F3,55=44.8, P<0.05), sex  (F1,55=30.1, P<0.05) and nociceptive stimulus 
intensity (F3,165 = 4.0, P<0.05), whereas there was no stimulus presentation x sex interaction.  
In both males and females, temporal summation was observed at each of the ISIs, 
with the 3.0 sec interval producing the largest effect and the 12 and 24 sec intervals the 
smallest effect (Fig. 2B). The magnitude of temporal summation was generally greater in 
males than in females, but this sex difference was not significant. Analyses of all tests 
conducted with the ISIs confirmed a main effect for ISI (F3,52=44.34, P<0.05), but not for sex 
or ISI x sex interaction. 
   Temporal summation was apparent at each of the nociceptive stimulus durations 
tested with the magnitude of this effect being slightly larger in males than females (Fig. 2C). 
The level of temporal summation did not systematically increase or decrease with increases 
in the nociceptive stimulus duration, but rather was characterized by a U-shaped function. 
Analyses confirmed a main effect for duration of the nociceptive stimulus (F2,40=19.3, 
P<0.05), sex (F1,40=24.9, P<0.05), nociceptive stimulus intensity (F3,120=5.37, P<.05) as well 
as a duration of the nociceptive stimulus x sex interaction (F2,40=4.0, P<0.05).  
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Temporal summation: Duration 
The duration of temporal summation under conditions in which tests were conducted 
at intervals ranging from 3.0 to 60 secs after the final presentation of the nociceptive stimulus 
was tested. The level of temporal summation systematically declined with increases in 
duration of the test interval (Fig.3). Temporal summation was evident at the 3.0 sec test time, 
only slightly below baseline at the 15 sec test time, and back to pre-temporal summation 
baseline levels at the 30, or 60 sec test times. Analyses of these data confirmed a main effect 
for sex (F1,56=5.09, P<0.05) and test time (F3,56=21.13, P<0.05), but no ISI x time of temporal 
summation test interaction.  
 
Temporal Summation: Allodynia 
A comparison of the level of temporal summation in males and females using a  non-
noxious (45ºC) and a noxious (51ºC) intensity was made to determine if heightened 
sensitivity to a non noxious stimulus would develop. Following 8 presentations of the 51ºC 
water, high levels of temporal summation were observed in the 51ºC test, but temporal 
summation was not evident in the test with non-noxious, 45ºC, stimulus (Fig. 4). Analysis 
indicated a main effect of nociceptive only for stimulus intensity (F1,14=211.3, P<0.05), sex 
(F1,14=13.9, P<0.05) and a sex x temperature interaction (F1,14=13.9, P<0.05).  Thus, repeated 
presentations of a noxious stimulus induced temporal summation of nociception but not 
allodynia. 
 
Temporal Summation: Gonadal hormone depletion 
For intact and gonadectomized females, temporal summation levels increased with 
increasing nociceptive stimulus intensities (F5,60=56.3, P<0.05) (Fig. 5). The level of 
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temporal summation was greater in gonadectomized females than their intact counterparts 
(F1,12=19.0, P<0.05) and there was an interaction of treatment condition with nociceptive 
stimulus intensity (F5,60=6.1, P<0.05). For both intact and gonadectomized males, temporal 
summation levels increased with increasing nociceptive stimulus intensities (F5,65 = 93.4, 
P<0.05), but there was no treatment condition x temperature interaction (F5,65=0.92, P>0.05). 
The level of temporal summation was higher in gonadectomized males than their intact 
counterparts (F1,13=8.9, P<0.05), although the magnitude of this effect was extremely small 
and not observed at all the nociceptive stimulus intensities.  
 
NMDA Antagonists 
 
To determine if the NMDA antagonists ketamine, dizocilpine and dextromethorphan 
produced antinociceptive effects, these drugs were tested in the warm water tail-withdrawal 
procedure (baseline conditions for the temporal summation procedure) using 51ºC water.  
Across the doses examined, these NMDA antagonists failed to produce greater than a 9% 
antinociceptive effect (data not shown) in either males or females.  
Low doses of these compounds produced only small changes in the level of 
antihyperalgesia (data not shown), whereas the higher doses (Fig. 6) reduced the level of 
temporal summation with the magnitude of this effect being consistently larger at the 49 then 
51ºC water and slightly greater in females. At no dose or water temperature tested was 
temporal summation eliminated in either the males or females. Analyses confirmed a main 
effect of the drugs on the level of temporal summation (F3,105=903.2, P<0.05), a main effect 
of nociceptive stimulus intensity (F1,105=35.3, P<0.05) and a main effect of sex (F1,105=6.0, 
P<0.05). Note that at the 49ºC water, baseline tail-withdrawal latencies approached the cut-
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off (15 sec) imposed in this procedure, and thus tests of antinociceptive effects of the various 
NMDA antagonists could not be evaluated. 
 
Opioids 
Morphine, buprenorphine, butorphanol and spiradoline produced dose-dependent 
increases in antinociception in the warm water tail-withdrawal (51ºC) procedure, with the 
highest doses tested producing maximal or near maximal effects (Fig. 7). The ED50 values 
(95% confidence limits) for these opioids in the warm water tail-withdrawal procedure were 
generally larger in males than females, with an analysis of potency ratios indicating the less 
efficacious opioids buprenorphine and butorphanol were more potent (P<0.05) in males than 
females (Table 3). 
Similarly, in the temporal summation procedure these opioids produced a dose-
dependent antihyperalgesic effect, with the highest dose tested generally producing tail-
withdrawal latencies comparable to baseline levels (Fig. 8). That is, these opioids completely 
reversed the hyperalgesia produced by the temporal summation procedure. These opioids 
were equally efficacious in males and females, and there were no sex differences (P<0.05) in 
opioid potency in the temporal summation procedure (Table 3). 
Comparison between males and females generally indicated sex differences in opioid 
sensitivity that was dependent upon the nociceptive procedure and type of opioid tested. In 
males, morphine, buprenorphine and butorphanol were more potent in producing 
antinociceptive effects than antihyperalgesic effects. The opposite effect was obtained in 
females, as these opioids were more potent in producing antihyperalgesic effects. In both 
males and females, the κ opioid spiradoline was more potent the antinociception procedure. 
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Discussion 
 
 As observed in humans, temporal summation in rats was rapidly established and 
demonstrated to be sensitive to changes in the frequency, intensity, ISI, and time of testing 
following the final presentation of the nociceptive stimulus. Across the range of parameters 
tested, the magnitude of the temporal summation was slightly greater in males than females. 
Moreover, temporal summation appeared to be modulated, in part, by the NMDA system, as 
evidenced by the ability of NMDA receptor antagonists to attenuate its development. Various 
opioids reduced the development of temporal summation, but there was no sex difference in 
either their potency or effectiveness.  
 A critical variable in the development of temporal summation in humans is the ISI, 
with temporal summation being most evident when the nociceptive stimulus is presented 
with intervals of less than 3.0 secs (Price 1977; Vierck et al. 1997; Staud et al. 2001; Sarlini 
and Greenspan 2002). The intervals most and least effective in producing temporal 
summation have been shown to correspond closely with those observed in assays of wind-up 
(Herrero et al. 2000), lending support to a relationship between temporal summation and 
wind-up. Consistent with these observations is the present finding that an ISI interval of 3.0 
secs produced the highest level of temporal summation in rats. Although temporal 
summation was still apparent at an ISI of 24 secs, the magnitude of this effect was extremely 
small.  
 Temporal summation in the rat was also sensitive to the number of presentations of 
the nociceptive stimulus, with the smallest effect obtained following a single presentation of 
the nociceptive stimulus and the largest following 4-12 presentations. Similarly, enhanced 
perception of pain with progressive presentations of the nociceptive stimulus is also a 
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characteristic of temporal summation in humans with maximal levels of temporal summation 
typically reached after 6-30 repetitions (Vierck et al. 1997; Fillingim et al. 1998; Edwards 
and Fillingim 2001).  
  The intensity of the nociceptive stimulus also had a significant effect on the 
development of temporal summation, with increases in water temperature producing 
increases in the magnitude of the temporal summation. At the lowest temperature tested, 
45ºC, temporal summation was not observed, a finding consistent with this temperature being 
a non-noxious stimulus (Falcon et al. 1996) and studies reporting the absence of temporal 
summation following presentations of non-noxious stimuli (Vierck et al. 1997; Edwards and 
Fillingim 2001). There are numerous studies indicating that in humans the level of temporal 
summation increases across thermal nociceptive stimulus intensities ranging from 45-53ºC 
(Vierck et al. 1997; Edwards and Fillingim 2001).  
 Previous investigations indicate that temporal summation established using a thermal 
stimulus can produce after-sensations, such as a burning or hot feeling, that can persist for 
approximately 15 secs in healthy controls and for 2 mins in patients with fibromyalgia (Staud 
et al. 2001). Pain ratings are also elevated in patients with fibromyalgia 60 secs after the 
establishment of temporal summation (Staud et al. 2003). Although subjective assessments of 
pain cannot be made in rats, tests of nociceptive sensitivity were conducted at varying 
intervals following the final presentation of the nociceptive stimulus. As observed in humans, 
the level of temporal summation in rats decayed after 3.0 secs with a return to baseline by 30 
secs. Collectively, these findings demonstrate a strong similarity between humans and non-
humans in the factors that modulate temporal summation, including ISI, nociceptive stimulus 
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intensity, number of presentations of the nociceptive stimulus and duration of nociceptive 
sensitivity. 
    Across various parametric manipulations, male rats exhibited a slightly greater level 
of temporal summation than females, at least when analyses took into account sex differences 
in baseline latencies. These findings are somewhat surprising considering that human females 
exhibit higher levels of temporal summation than males (Fillingim et al. 1998; Sarlini and 
Greenspan 2002). It has been suggested that these higher levels in females reflect enhanced 
central hyperexcitability of nociceptive processing which, in turn, may predispose females to 
the development of certain chronic pain conditions. Indeed, the prevalence of fibromyalgia, 
migraines and other chronic pain conditions are higher in females (Unruh 1996). Female 
rodents are also more likely to develop certain persistent pain conditions, such as neuropathic 
pain following partial sciatic nerve ligation and autoimmune diseases (Coyle et al. 1995; 
Verthelyi et al. 2001). Although there are a number of procedural differences in the temporal 
summation procedure used in humans and rats, one critical difference is that humans are 
required to give a verbal pain rating in response to the nociceptive stimulus (Arendt-Neilsen 
et al. 1995; Graven-Nielsen et al. 2000; Staud et al. 2001; Price et al. 2002) and it is well 
established that pain has a prominent, sex-dependent emotional component (Riley et al. 
2000). In fact, Robinson et al. (2004) recently reported that sex differences in temporal 
summation in humans are influenced by sex differences in anxiety levels and gender role 
stereotypes. Importantly, when these factors are taken into account, sex does not function as 
a predictor of levels of temporal summation. 
  In contrast to studies conducted in humans, in the present study sensitivity to the 
nociceptive stimulus in rats was inferred from a decrease in the tail-withdrawal latency from 
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warm water. Moreover, testing was initiated only after an extensive habituation procedure, 
thus minimizing potential sex differences in stress or emotional responsiveness (Dhabhar et 
al. 1997). It is important to note that while temporal summation in humans is considered to 
be a correlate of wind-up, at this time there has been no exploration of sex differences in 
wind-up therefore comparison of sex difference in this model and wind-up are not possible. 
 Receptors for sex hormones are widely distributed throughout the CNS and are 
known to have an effect on nociceptive pathways. For example, gonadal hormones can affect 
nociceptive sensitivity in models of both acute and chronic nociception using chemical, 
thermal and mechanical stimuli (Fry et al. 1993; Gaumond et al. 2002; Aloisi 2003; Barrett et 
al. 2003; Terner et al. 2003; Vinogradova et al. 2003). Although this issue has not been 
specifically addressed in humans, there is evidence that the elderly display a greater level of 
temporal summation than younger individuals, thus there is the possibility that depletion of 
gonadal hormones associated with aging may contribute to this phenomenon (Edwards and 
Fillingim 2001; Staud et al. 2001). In the present investigation, the level of temporal 
summation in gonadectomized females was greater than those in intact females. In contrast, 
gonadectomy had minimal effects on temporal summation in males, a finding suggesting that 
male gonadal hormones may not be directly involved in the development of temporal 
summation. The reasons for these differential effects of hormones remain unclear.  
 Wind-up and temporal summation are both models used to investigate the central 
mechanisms thought to underlie the pathophysiology of chronic pain. Attenuation of wind-up 
and temporal summation of pain in humans by the administration of NMDA antagonists has 
been used to suggest the contribution of the NMDA system and its central involvement 
(Dickenson and Sullivan 1987; Price et al. 1994; Arendt-Nielson et al. 1995; Graven-Neilson 
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et al. 2000; Guirimand et al. 2000). In the present investigation, administration of various 
non-competitive NMDA antagonists decreased the level of temporal summation in a 
generally dose-dependent manner. This effect was observed in both males and females at 
doses of the NMDA antagonists that failed to produce an antinociceptive effect. The 
magnitude of this effect appears comparable in both humans and rats, with complete 
blockade of temporal summation not obtained under any of the conditions tested. Although 
the adverse side effects of NMDA antagonists typically limit the testing of high doses in 
humans, even the relatively high doses tested in rats failed to completely block the 
development of temporal summation. Whereas these findings provide evidence that the 
NMDA system plays a modulatory role in the development of temporal summation, they also 
suggest that other systems are involved in this process.  
In humans, the opioids morphine, codeine and pentazocine have been reported to be 
effective in reducing the development of temporal summation, with pentazocine being 
equally potent in both males and females (Price et al. 1985; Enggaard et al. 2001; Fillingim et 
al. 2004). Similarly, in the present investigation the µ opioids morphine and buprenorphine, 
the mixed-action opioid butorphanol and the κ opioid spiradoline were effective in reducing 
temporal summation. Moreover, each of these opioids were equally potent in males and 
females. Temporal summation is thought to reflect the development of central sensitization 
and thus is considered a model of some types of chronic pain (e.g., Ren 1994; Li et al. 1999). 
As such, the present findings extend a recent report indicating the absence of sex differences 
in opioid sensitivity in model of chronic pain. Indeed, in rats morphine, buprenorphine and 
dezocine were found to be equally potent and effective at reducing the hyperalgesia induced 
by the administration of capsaicin (Barrett et al. 2003). Presently, it is unclear as to whether 
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the temporal summation procedure and the capsaicin-induced hyperalgesia can be considered 
models of long-term pain, as in rats the duration of the hyperalgesic effect is relatively short-
lived. 
In contrast to the findings obtained in the temporal summation procedure, in the warm 
water tail-withdrawal procedure, a model of acute pain, both buprenorphine and butorphanol 
were more potent in producing antinociception in males. Such effects were not consistently 
observed with the µ opioid morphine or the κ opioid spiradoline. These findings extend a 
large body of evidence indicating that in non-humans, males are generally more sensitive 
than their female counterparts to the antinociceptive effects of opioids in models of acute 
pain and that these sex differences are most evident with less efficacious opioids (Negus and 
Mello 1999; Cook et al. 2000; Craft and Bernal 2001; Terner et al. 2003). Such findings 
provide strong support for the idea that different mechanisms underlie sex differences in 
opioid sensitivity in acute and chronic models of pain.  
The present investigation describes a simple method of establishing temporal 
summation in rats. In addition to demonstrating the generality of temporal summation across 
species, the similarities of temporal summation in humans and rats allow for number of 
potential applications of this model. Of particular importance is that this model can be 
adapted to screen novel pharmacological treatments for chronic pain and to identify the 
factors that modulate the effectiveness of different treatment approaches. For example, the 
present findings identified a potential role for sex in determining the potency of opioids in 
the treatment of chronic pain, as analyses indicated that in males the µ opioids tested were 
generally more potent in producing antihyperalgesia than antinociception, whereas in females 
the µ opioids were generally more potent in producing antinociception. 
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This model can also be used to explore the mechanisms underlying the development 
of some chronic pain conditions as well as the factors that can modulate these conditions 
(e.g., age, sex, health status). For example, in the present study the effectiveness of NMDA 
antagonists was dependent upon nociceptive stimulus intensity, with greater levels of 
attenuation observed at a relatively low nociceptive stimulus intensity. Such findings may 
help explain the varying levels attenuation produced by NMDA antagonists observed in 
studies of human temporal summation, and suggest that high nociceptive stimulus intensities 
may require activation of NMDA and non-NMDA systems. Additionally, whereas NMDA 
antagonists have played a key role in establishing the importance of the NMDA system in 
modulating chronic pain models, these compounds are relatively non-selective and thus this 
model of temporal summation may allow identification of the critical NMDA receptor 
subtypes (e.g., see Kovacs et al. 2004).  
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Table 1. Baseline tail withdrawal latencies (standard error) expressed in seconds for male and 
female rats  (N = 7-8) in the warm water tail-withdrawal procedure.  
 
 
Warm Water 
Temperature 
 
Males 
  
Females 
45oC  15.00 (0.0) 14.47 (0.53) 
47oC  13.56 (0.56) 11.87 (1.03) 
49oC  13.24 (0.87) 10.85 (0.91) 
50oC  10.67 (1.1)    8.50 (0.54)  
51oC  10.00 (0.83)   6.72 (0.57) 
52oC    8.00 (0.87)   6.34 (0.55) 
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 Table 2. Testing conditions for the temporal summation procedure 
 
 
Testing 
Condition 
Number of 
Stimulus 
Presentationsb  
Inter-
Stimulus 
Intervalc
(sec) 
Stimulus 
Durationd
(sec) 
Test 
Intervale
(sec) 
Stimulus 
Intensitya
(Co) 
Stimulus 
Intensitya
8 3 3 3 45,47,49,50,51,5
2 
Number of 
Stimulus 
Presentationsb
 
   1,4,8,12 
 
3 
 
3 
 
3 
 
49,50,51,52 
Inter-
Stimulus 
Intervalc
8 3,6,12,24 3 3 49,50,51,52 
Stimulus 
Durationd
8 3 0.5,1,3 3 49,50,51,52 
Test Intervale 8 3 3 3,15,30,60 51 
NMDA 
Antagonist 
8 3 1 3 49,51 
Opioids 8 3 1 3 51 
 
a Water temperature 
b Number of times the tail was placed in warm water 
c Time between when the tail was removed from the warm water and placed back in warm water 
d Length of time in which the tail was placed  in warm water 
e Time between the final presentation of the nociceptive stimulus and when the test for temporal summation 
was  conducted 
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Table 3. ED50 (mg/kg) values (95% confidence limits) for male and female rats (n=6-8)  
in tests of antinociception (warm water tail-withdrawal) and antihyperalgesia (temporal 
summation procedure) conducted with morphine, buprenorphine, butorphanol and 
spiradoline. 
  
 
Drug     Antinociception  Antihyperalgesia 
 
Morphine     
  Male     4.58 (3.43-6.12)  5.19 (4.10-6.58) 
  Female    5.90 (5.06-6.90)  5.50 (4.43-6.85) 
 
Buprenorphine 
  Male     0.01 (0.000012-15.19)* 0.22 (0.04-1.23) 
  Female    0.6 (0.36-0.99)  0.55 (0.35-0.87) 
 
Butorphanol 
  Male     5.84 (1.92-17.75)*  9.91 (4.69-20.92) 
  Female    16.17 (9.29-28.14)  11.2 (6.70-21.22) 
 
Spiradoline 
  Male     24.07 (17.91-32.35)  14.47 (10.13-20.69) 
  Female    31.82 (14.31-70.72)  18.31 (14.17-23.66) 
 
* Significant difference from females at the 0.05 level as determined by potency ratios  
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Figure 2.1 Tail-withdrawal latencies for male and female rats (7-8 animals per group) in the 
temporal summation procedure following repeated presentations of the warm water stimulus 
at temperatures ranging from 45 to 52ºC. For all tests, the warm water stimulus was 
presented 8 times with each presentation lasting 3.0 secs and an inter-stimulus interval of 3.0 
secs. The temporal summation test was conducted 3.0 secs after the final presentation of the 
warm water stimulus. All data are expressed as percent of baseline tail withdrawal latencies 
assessed prior to the start of the temporal summation procedure. A value of 100% indicates 
that the tail-withdrawal latency in the temporal summation procedure was comparable to that 
obtained prior to the repeated presentation of the warm water stimulus. Values of less than 
100% indicate that repeated presentations of the warm water stimulus produced a decrease in 
the tail withdrawal latency indicative of hyperalgesia. Vertical bars represent the standard 
error; where not indicated, the standard error fell within the data point. 
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Figure 2.2 Effects of various parametric manipulations on the magnitude of temporal 
summation in male and female rats (7-8 animals per group). All data are expressed as percent 
of baseline tail-withdrawal latencies assessed prior to the start of the temporal summation 
procedure. Unless indicated (see below), in all tests the warm water stimulus was presented 8 
times with each presentation lasting 3.0 secs and an inter-stimulus interval of 3.0 secs. The 
temporal summation test was conducted 3.0 secs after the final presentation of the warm 
water stimulus. For all panels, vertical bars represent the standard error; where not indicated, 
the standard error fell with the data point. Panel A: Tail-withdrawal latency for the temporal 
summation procedure in which the number of presentations of the warm water ranged from 1 
to 12. Panel B: Tail-withdrawal latency for the temporal summation procedure in which the 
interval between warm water stimulus presentations (inter-stimulus interval) ranged from 3.0 
to 24 secs. Panel C: Tail-withdrawal latency for the temporal summation procedure in which 
the duration of exposure to the warm water stimulus ranged from 0.5 to 3.0 secs.  
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Figure 2.3 Tail-withdrawal latency in the temporal summation procedure in male and female 
rats (7-8 animals per group). Tests were conducted at intervals ranging from 3.0 to 60 secs 
after the final presentation of the warm water stimulus (51ºC). For all tests, the warm water 
stimulus was presented 8 times with each presentation lasting 3.0 secs and an inter-stimulus 
interval of 3.0 secs. All data are expressed as percent of baseline tail withdrawal latencies 
assessed prior to the start of the temporal summation procedure. Vertical bars represent the 
standard error; where not indicated, the standard error fell within the data point. 
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Figure 2.4 Effects of repeated presentation of a noxious stimulus (51ºC water) on the 
development of temporal summation and allodynia  in males and females rats (7-8 per 
group). For all tests, the 51ºC warm water stimulus was presented 8 times with each 
presentation lasting 3.0 secs, and an inter-stimulus interval of 3.0 secs. The final presentation 
of the warm water stimulus was followed by the tail withdrawal latency test using either 45 
(non-noxious) or 51ºC warm water. For both males and females, a test temperature of 45ºC 
produced tail-withdrawal latencies equal to that of baseline tail-withdrawal latencies. All data 
are expressed as percent of baseline tail-withdrawal latencies assessed prior to the temporal 
summation procedure. Vertical bars represent the standard error; where not indicated, the 
standard error fell within the data point. 
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Figure 2.5 Effect of a sham operation (intact) and gonadectomy on the level of temporal 
summation in male and female rats (7-8 per group) using water temperatures ranging from 
45-52ºC. All data are expressed as percent of baseline tail-withdrawal latencies assessed prior 
to the temporal summation procedure for females (left panel) and males (right panel). For all 
tests, the warm water stimulus was presented 8 times with each presentation lasting 3.0 secs, 
and an inter-stimulus interval of 3.0 secs. The temporal summation tail-withdrawal latency 
test was conducted 3.0 secs after final presentation of the warm water stimulus. Vertical bars 
represent the standard error; where not indicated, the standard error fell within the data point. 
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Figure 2.6 The effects of saline and the NMDA antagonists ketamine (30 mg/kg), dizocilpine 
(0.1 mg/kg) and dextromethorphan (30 mg/kg) on the level of temporal summation in male 
and female rats (6-8 per group). The temporal summation procedure for these tests was 
performed 30 mins following injection and consisted of 8 repetitions of the warm water 
stimulus (49 and 51ºC), an inter-stimulus interval of 3.0 secs, using a 1.0 sec warm water 
stimulus duration, with the tail-withdrawal latency test conducted 3.0 secs following the final 
presentation of warm water stimulus. Saline data are expressed as percent of baseline tail-
withdrawal latency taken 30 mins following the administration. For ease of comparison, drug 
data are expressed as percent of saline baseline tail-withdrawal latencies. Only data for the 
highest dose of ketamine, dizocilpine and dextromethorphan are illustrated in the figure: 
these drugs had no effect on baseline tail-withdrawal latencies. Vertical bars represent the 
standard error; where not indicated, the standard error fell within the data point.  
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Figure 2.7 The effects of morphine, buprenorphine, butorphanol and spiradoline in male and 
females rats (6-8 per group) tested with a warm water, tail-withdrawal procedure at 51ºC.  
Vertical bars represent the standard error; where not indicated, the standard error fell within 
the data point.  
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Figure 2.8 The effects of morphine, buprenorphine, butorphanol and spiradoline in male and 
females rats on the level of temporal summation in male and female rats (6-8 per group).  
The temporal summation procedure for these tests was performed 30 mins following 
injection and consisted of 8 repetitions of the warm water stimulus (51ºC), an inter-stimulus 
interval of 3.0 secs, using a 1.0 sec warm water stimulus duration, with the tail-withdrawal 
latency test conducted 3.0 secs following the final presentation of warm water stimulus. Data 
are expressed as percent antihyperalgesic effect, 100% antihyperalgesic effect reflects a 
temporal summation tail-withdrawal latency with drug equal to that of saline baseline tail-
withdrawal latency. Vertical bars represent the standard error; where not indicated, the 
standard error fell within the data point. 
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CHAPTER 3 
EXPERIMENT 2: SEX DIFFERENCES IN THE POTENCY OF κ OPIOIDS AND 
MIXED-ACTION OPIOIDS ADMINSTERED SYSTENICALLY AND AT THE SITE 
OF INFLAMMATION IN A CAPSAICIN-INDUCED MODEL OF HYPERALGESIA 
  
Introduction 
 There is now evidence that male and female rodents differ in their sensitivity to the 
antinociceptive effects of κ opioids (e.g., Craft and Bernal 2001; Holtman and Wala 2006). In 
a recent review and analysis, Craft (2003) reported that when collapsed across drugs, studies 
and species, 39% of the reports indicated that κ opioids were more potent in males, 50% 
equally potent in males and females, and 11% more potent in females. Both the direction and 
magnitude of these sex differences appear to be influenced by the dose, type of κ opioid, 
genotype, and type of pain model (for reviews see Craft 2003; Barrett 2006). In rats, for 
example, reports of κ opioids being more potent in males have appeared exclusively in 
studies utilizing acute pain models and are more likely to occur when complete dose-effect 
functions are determined. Although there are only two reports in which κ opioids were 
examined in persistent pain models, in these studies the κ opioids tested were either more 
potent in females or equally potent in males and females (Binder et al. 2000; Clemente et al. 
2004).  
Presently, it is unclear if these conflicting findings are a consequence of a sexually-
dimorphic interaction of opioids with the distinct mechanisms underlying acute versus 
persistent nociception. For example, persistent nociception requires activation of 
unmylenated C-fibers and acute nociception activation of large Aδ nociceptive fibers (e.g., 
LeBars et al. 2001). Acute and persistent nociception also differ in terms of their duration, 
neurochemical substrates, and sensitivity to pharmacological manipulation (LeBars et al. 
2001; Richardson and Vasko 2002; Mogil et al. 2003). Thus, the primary goal of the present 
investigation was to evaluate sex differences in the effects of κ opioids and selected mixed-
action opioids with low efficacy at the κ receptor in a persistent pain model. To this end, we 
conducted tests using the capsaicin-induced hyperalgesia procedure, which is a persistent 
pain model adapted to the study of sex differences in µ opioid sensitivity (Barrett et al. 
2003). One limitation of some persistent pain models is that it is often difficult to control the 
level of nociception, and baseline levels of nociception are known to be a determinant of sex 
differences in opioid sensitivity (Cook et al. 2000; Barrett et al. 2002). By altering the dose 
of capsaicin, however, it is possible to produce comparable levels of nociception in males 
and females (Barrett et al. 2003). Moreover, inflammation is localized to the tail in the 
capsaicin model and thus it is possible to examine sex differences in the effects of relatively 
small doses of κ opioids when their actions are directed at κ opioid receptors located at the 
site of inflammation. From a clinical perspective, a result of administering small doses 
locally is that it minimizes potential adverse effects, which is especially critical for κ opioids 
as adverse central effects limit their clinical utility (Kumor et al. 1986; Rimoy et al. 1991).  
Although the mechanisms that mediate the sexual dimorphism in κ opioid sensitivity 
are unclear, several studies have implicated the NMDA receptor system. Indeed, NMDA 
antagonists attenuate κ opioid antinociception in male mice and rats but not intact females 
(Kavaliers and Choleris 1997; Mogil et al. 2003; Holtman and Wala 2006). Ovariectomized 
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female mice (Sternberg et al. 2004) display a similar sensitivity to NMDA antagonists as 
males, suggesting further that males and females have similar opioid/nociceptive circuitry, 
but in females the NMDA component of this circuitry is actively suppressed by the gonadal 
hormones. 
To date, studies of NMDA involvement in sex differences of κ opioid antinociception 
have been conducted exclusively in models of acute pain and thus its contribution to 
persistent pain remains to be determined. Experiments of this nature can be complicated by 
the fact that NMDA antagonists have a direct effect on the development of persistent 
nociception induced by injections of formalin and Freund’s adjuvant, as well as in post-
surgical nociception (Eisenberg et al. 1993; Przewlocki and Przewlocki 2001; Nishimura et 
al. 2004). Such effects are not observed following the administration of capsaicin (Sakurada 
et al. 1998), and thus this persistent pain model may provide an opportunity to evaluate the 
contribution of the NMDA system to sex differences with κ opioids. For comparison, tests 
were conducted in a 50°C warm water tail-withdrawal procedure as in this procedure NMDA 
antagonists antagonize the effects of κ opioids in a sexually dimorphic manner (Mogil et al. 
2003; Holtman and Wala 2006). 
 
Methods 
Animals 
Gonadally intact male and female F344 rats were obtained from Charles River Laboratories 
(Raleigh, NC, USA).  F344 rats were chosen as previous studies in our lab utilizing this 
strain have shown large sex differences in opioid antinociception. All testing occurred 
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between 3 and 6 months of age, and rats were individually housed in a colony on a 12-h/12-h 
light/dark cycle.  All rats had unlimited access to food and water. 
 
Apparatus and testing 
A warm-water tail withdrawal procedure was used to assess hyperalgesia.  Before 
testing, rats were habituated to handling on one occasion.  During testing, each rat was lightly 
restrained, with the distal 7 cm of the tail immersed in water maintained at 45ºC. This 
temperature was selected as it approximates threshold nociceptive values in adult rats (Falcon 
et al. 1996). Baseline tail withdrawal latencies were determined in each rat before 
administration of any compounds, and rats that failed to maintain their tails in the water for a 
full 15 secs were excluded from testing. Subsequently, capsaicin was injected 3.5 cm from 
the tip of the tail. All injections of capsaicin were made under light halothane anesthesia, 
with rats recovering from this procedure within 2-3 mins. Following administration of 
capsaicin, tail-withdrawal latencies decreased from 15 sec to approximately 3.5 - 4.5 secs 
with this effect being consistent in both males and females. Rats were tested once per week 
with no more than 5 tests per animal. Previous studies conducted in our laboratory indicated 
that this frequency of testing and the number of tests produced reliable and consistent tail-
withdrawal latencies (Barrett et al. 2003).  
 
Antihyperalgesic effects of opioids 
For tests examining the antihyperalgesic effects of opioids, a 3.0 and 1.0 µg dose of 
capsaicin was chosen for males and females, respectively, as these doses produce a 
comparable magnitude and duration of hyperalgesia (Barrett et al. 2003). Before initiating 
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testing of opioids, a capsaicin baseline was assessed in each animal. To determine the 
antihyperalgesic effects of opioids and to determine potency differences in local versus 
systemic administration, capsaicin was administered in the tail, and one dose of each opioid 
was injected systemically (s.c.) or locally in the tail. Tail-withdrawal latencies were 
determined 15 min after the capsaicin/opioid injection, which is the time point corresponding 
to the peak effect of capsaicin. Additional tests were conducted in which the non-competitive 
NMDA antagonist dextromethorphan was administered (s.c. or tail) 15 mins prior to 
capsaicin injection alone or in combination with U69,593 (s.c. or tail).  For all tests, a 15 s 
cutoff latency was implemented, as this indicated a maximal antihyperalgesic effect (i.e., 
nociceptive thresholds returned to baseline levels). The doses of dextromethorphan selected 
for study are similar to those used in previous studies (e.g., Holtman et al. 2003; Craft and 
Lee 2005), as higher doses are  known to alter locomotor activity as well as produce ataxia 
and stereotypies (Dansysz et al. 1994; Plesan et al. 1998; Redwine and Trujillo 2003). 
 
Antihyperalgesic activity of κ opioids at the site of inflammation 
To examine the local mediation of locally administered opioids, doses that produced 
high levels of antihyperalgesia in males and females were administered in the tail along with 
either local or i.c.v. administration of the selective κ antagonist nor-BNI. For tests with i.c.v 
administration of nor-BNI, nor-BNI was administered 24 hrs before capsaicin. For tests with 
local (in tail) administration, nor-BNI was administered 15 min before capsaicin. Due to the 
long duration of nor-BNI, testing for an individual rat was terminated after the completion of 
this test. In order to provide a comparison between the results obtained in this persistent pain 
model with those in an acute pain model, and to identify the dose of nor-BNI to be 
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administered i.c.v. in tests of local mediation of antihyperalgesia, additional tests were 
conducted using a warm water tail-withdrawal procedure. In this procedure, rats were placed 
in restraint tubes with the distal 7 cm of the tail immersed in 50°C water and latency to 
remove the tail measured (see Cook et al. 2000 for details). Tail withdrawal latencies were 
typically between 10 - 11 secs in both males and females. After baseline latencies were 
assessed, U69,593 was administered and the latency to remove the tail from the 50°C warm 
water was determined. A 15-s cut-off to tail-withdrawal was imposed to avoid tissue damage.  
For these tests, nor-BNI was administered i.c.v. 24 hrs before administration of U69,593. 
 
Data analysis 
For dose-effect curves examining the antihyperalgesic effects of opioids, latencies to 
tail-withdrawal following administration of the drug were converted to the percentage of the 
maximum possible effect using the following equation: % antihyperalgesic effect = 
[(observed-baseline)/(15 s-baseline)] x 100.  When possible, the dose of each drug required 
to produce a 50% antihyperalgesic effect (ED50) was derived mathematically (least-squares 
method) using log-linear interpolation with at least three doses on the ascending limb of the 
dose-effect curve.  For each opioid, an ANOVA was also conducted with sex and dose as 
between-groups factors.  In instances in which there was a main effect for sex, post-hoc tests 
were conducted using the Fisher’s protected least significant difference test to assess the 
effect of sex on each dose of the opioid. For statistical analyses using ANOVA, the alpha 
level was set at 0.05. Relative potency estimates were also calculated by comparing the 
potency of s.c. administration of opioids with local administration of opioids within males 
and within females. For this analysis, dose ratios were calculated in a manner described by 
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(Tallarida and Murray 1987), in which a common slope was determined between linear 
regression lines representing the 2 dose-effect curves, and then the distance between the 
regression lines calculated. Differences in the relative potency of s.c. and tail administration 
of opioids were considered to be significant if the 95% confidence interval did not overlap 
1.0 (by using a t test). 
To calculate the % maximal antinociceptive effect, tail-withdrawal latencies for the 
50ºC warm water tail-withdrawal procedure were converted to percent antinociceptive effect 
using the following equation: % antinociceptive effect = [(test latency - baseline) / (15 s - 
baseline)] X 100. The time-course evaluation of a drug’s effect was measured in this assay 
with an ANOVA on area under the curve used for statistical analysis. Area under the curve 
was estimated by the Trapezoidal Rule using available statistical software (Tallarida and 
Murray 1987).  
  
Intracerebroventricular Injections 
Rats were stereotaxically implanted with a single 22-gauge cannula into the left 
lateral ventricle [anterior-posterior (AP) +0.9, medial-lateral (ML) +1.5, dorsal-ventral (DV) 
–3.2] under anesthesia induced with a 1 ml/kg injection of a 1:1 (v/v) mixture of ketamine 
(100 mg/ml) and xylazine (20 mg/ml).  Coordinates are expressed at millimeters from 
bregma (Paxinos and Watson 1986). Rats were given i.c.v. injections of nor-BNI in a 5 µl 
volume with a 28-gauge injector that protruded 1 mm beyond the tip of the cannula.  The 
injector was connected by a length of tubing to a 10 µl Hamilton microsyringe.  
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Drugs 
The following drugs were used: nor-binaltorphamine, trans-3,4-dichloro-N-methyl-
N[2-(1-pyrolidinyl)cyclohexyl] benzeneaceamide methanesulfonate (U50,488) (all provided 
by the National Institute on Drug Abuse), dextromethorphan hydrobromide monohydrate, 
spiradoline mesylate, butorphanol tartrate, nalbuphine HCl, 1-oxaspiro[4,5]dec-8-yl 
benzeneacetamide (U69,593), and capsaicin (all purchased from Sigma-Aldrich Co., St. 
Louis, Mo.). Capsaicin was dissolved in a solution of Tween 80/95% ethanol/saline in a ratio 
of 1/1/8, and was diluted to lower concentrations with saline.  For injection in the tail, 
capsaicin (0.1 ml volume when administered alone) was mixed in the same syringe as the test 
drugs in a 0.1 ml volume. For other tests, drugs were administered s.c. in a volume of 0.5-1.0 
ml/kg.  
 
Results 
κ opioids  
Fig. 1 shows that in both males and females the κ opioids spiradoline, U50,488 and 
U69,593 produced dose-dependent increases in antihyperalgesia, with maximal or near 
maximal effects obtained at the highest doses tested. As shown in Table 1, spiradoline was 
the most potent of the κ opioids in both males and females when administered locally, 
whereas U69,593 and U50,488 were approximately equally potent. In contrast, when 
administered systemically U50,488 was the most potent, whereas spiradoline and U69,593 
were approximately equally potent. Table 2 shows that sex differences were observed in the 
potency of these κ opioids, with the antihyperalgesic potency of systemic and local 
administration of spiradoline and U50,488 being greater in males. Analyses based on 
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ANOVA for spiradoline confirmed these observations, indicating a main effect for sex 
(systemic: F1,12=10.3, P<0.05; local: F1,12=4.7, P<0.05) and dose (systemic: F1,24=23.9, 
P<0.05; local: F1,24=39.5, P<0.05), but no dose x sex interaction. Similarly, a main effect for 
dose (systemic: F2,24=61.7, P<0.05; local: F2,26=27.2, P<0.05) and sex (systemic: F1,12=55.8, 
P<0.05; local: F1,13=4.5, P<0.05) was observed for U50,488. A significant dose x sex 
interaction was observed for systemic (F2,24=20.2, P<0.05) but not local, administration of 
U50,488. In contrast to spiradoline and U50,488, sex differences with U69,593 were 
observed only following local administration (F1,13=5.2, P<0.05). Analyses also revealed a 
main effect of dose (F2,26=156.4, P<0.05) and a dose x sex interaction (F2,26=3.4, P<0.05). 
Although there was no main effect for sex with systemic administration of U69,593 or a dose 
x sex interaction, there was a main effect for dose (F2,12=45.5,  P<0.05).  
 
Antihyperalgesic activity of κ opioids at the site of inflammation 
To determine the role of κ opioid receptors at the site of inflammation in mediating 
the antihyperalgesic effect of κ opioids, U69,593 was administered locally in combination 
with both local and i.c.v. administration of the κ antagonist nor-BNI. As shown in panels “a” 
and “b” of Fig. 2, the effects of U69,593 were attenuated by local but not i.c.v. administration 
of nor-BNI, suggesting that the effects of U69,593 were mediated by κ opioid receptors at the 
site of inflammation. ANOVAs indicated a main effect for treatment (F2,29=61.6, P<0.05) 
with post hoc analyses confirming attenuation by local (P<0.05) but not by i.c.v. 
administration. There was, however, no main effect for sex or a sex x condition interaction.  
 For comparison, and to determine if the dose of nor-BNI selected for i.c.v. 
administration was appropriate, similar tests were conducted in a 50ºC warm water tail-
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withdrawal procedure. In this procedure, systemic administration of opioids is known to 
produce antinociception via central and/or spinal sites. In order to equate the antinociceptive 
effects produced by U69,593, a higher dose was used in females (5.6 mg/kg) than males (3.0 
mg/kg). In this procedure, systemic administration of U69,593 produced a time-dependent 
antinociceptive response, with a peak effect observed 30 to 45 minutes after administration 
(Fig. 2, Panels “c” and “d”). Although complete dose-response testing was not conducted, 
with this higher dose the peak effect of U69,593 was slightly smaller in the females. In this 
procedure, local administration (i.e., in the tail) of U69,593 failed to produce an 
antinociceptive effect in either males or females. Administration of nor-BNI via the i.c.v. 
route completely attenuated the effects of U69,593, suggesting that in this procedure the 
effects of U69,593 were mediated by spinal or supraspinal κ opioids receptors. ANOVA 
indicated a main effect for treatment (F2,26=27.1, P<0.05) with post hoc analyses confirming 
attenuation (P<0.05) by i.c.v. administration of nor-BNI. Post hoc analyses also confirmed a  
difference (P<0.05) in the antinociceptive effects of systemic and local administration of 
U69,593 in the tail withdrawal procedure. No main effect for sex or a sex x condition 
interaction was found.  
Fig. 3 shows that in the capsaicin preparation, local administration of nor-BNI 
attenuated the antihyperalgesic effects of spiradoline in both males and females. In contrast, 
nor-BNI failed to attenuate the effects produced by U50,488. ANOVA indicated a main 
effect of drug condition for spiradoline (F1,23=22.5, P<0.05) but no main effect for sex or a 
sex x condition interaction.  
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Mixed-action opioids 
Fig. 4 shows that the mixed-action opioids butorphanol and nalbuphine produced 
dose-dependent increases in antihyperalgesia, with maximal or near maximal effects obtained 
at the highest dose tested. In both males and females, nalbuphine was more potent when 
administered locally, whereas butorphanol was more potent when administered locally in 
males but not in females (Table 2). ANOVA analyses indicated a main effect of dose for both 
drugs (butorphanol: systemic: F3,33=22.8, P<0.05, local: F3,39=42.8, P<0.05; nalbuphine: 
systemic: F2,24=27.3, P<0.05, local: F2,26=212, P<0.05), but no effect of sex or dose x sex 
interaction. Thus, in contrast to the κ opioids tested, there were no sex differences in the 
antihyperalgesic potency of either nalbuphine or butorphanol (see Table 1). 
Fig. 5 shows that local administration of nor-BNI attenuated the antihyperalgesic 
effects of nalbuphine in both males and females, but failed to attenuate the effects produced 
by butorphanol. ANOVA indicated a main effect for drug condition only for nalbuphine 
(F1,23=660, P<0.05), and no main effect for sex or a sex x condition interaction. Although 
nor-BNI failed to attenuate the effects of butorphanol there was a sex x condition interaction 
(F1,36=5.37, P<0.05). 
 
NMDA modulation of κ opioid antihyperalgesia 
To evaluate the sexually-dimorphic role of the NMDA system in modulating κ opioid 
antihyperalgesia, the NMDA antagonist dextromethorphan was administered in combination 
with both local and systemic administration of U69,593. Alone, dextromethorphan (3.0 - 30 
mg/kg) had no antihyperalgesic effects (data not shown). However, at the higher does tested 
there was a clear disruption of motor coordination and sedation. As shown in Fig. 6, in both 
 49
sexes systemic administration of dextromethorphan produced a dose-dependent attenuation 
of the antihyperalgesic effect of systemic administration of U69,593, with almost complete 
attenuation observed at the highest dose of dextromethorphan tested. ANOVA confirmed a 
main effect for dose (F3,46=39.33, P<0.05), but no main effect for sex or a sex x dose 
interaction. Post hoc analysis indicated a significant (P<0.05) difference between U69,593 
alone and the combination of U69,593 with 3.0 and 30 mg/kg dextromethorphan.  In 
comparison, as shown in Fig. 7, dextromethorphan administered systemically produced a 
small attenuation (less than 30%) of the antihyperalgesia produced by local administration of 
U69,593 in both sexes. Local administration of dextromethorphan also failed to attenuate the 
antihyperalgesia produced by local U69,593 administration in both males and females.  
ANOVA analysis indicated a main effect for treatment (F2,34=3.29, P<0.05), but no main 
effect for sex or a sex x treatment interaction. Post hoc analysis confirmed the combination of 
dextromethorphan administered systemically and U69,593 locally was  different (P<0.05) 
than U69,593 alone. 
Fig. 8 shows attenuation of the antihyperalgesic effects of both spiradoline and 
U50,488 in males and females by dextromethorphan. In these tests, the most effective dose of 
each opioid was combined with 30 mg/kg of dextromethorphan, with all drugs being 
administered systemically. ANOVA’s indicated a main effect for treatment with spiradoline 
alone and in combination with dextromethorphan, (F1,23=6.87, P<0.05), but no main effect 
for sex or a sex x dose interaction. ANOVA also indicated a main effect for treatment for 
U50,488 alone or in combination with dextromethorphan (F1,23=1.02, P<0.05), but no main 
effect for sex. There was a sex x treatment interaction (F1,23=14.737, P<0.05).  
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For comparison, tests were conducted in the 50ºC warm water tail-withdrawal 
procedure with all drugs being administered systemically. As shown in Fig. 9, equally 
effective doses of U69,593 were combined with a dose of dextromethorphan that produced 
the largest reduction in antihyperalgesia in the capsaicin preparation. In these tests, U69,593 
produced near maximal effects in both males and females. Dextromethorphan attenuated the 
antinociceptive effect produced by U69,593 only in males (F1,12=36.2, P<0.05). Comparison 
of difference scores in the area under the curve analysis confirmed this sexually dimorphic 
action. Thus, dextromethorphan attenuated the effects of U69,593 in both males and females 
in the capsaicin preparation, but in the 50ºC warm water tail-withdrawal procedure 
attenuation was observed only in males. 
 
Discussion 
Previous studies indicate that κ opioids generally produce greater antinociception in 
males compared to females, and this effect has been reported in rats, mice and monkeys 
(Craft 2003). Unfortunately, the available animal studies have almost exclusively utilized 
acute nociceptive models, and thus little is known about sex differences in the effectiveness 
of κ opioids in persistent pain models. Consequently, one purpose of the present 
investigation was to examine the antihyperalgesic effects of κ opioids following 
administration of capsaicin, which produces a short term (30-90 mins) hyperalgesic response 
to mildly noxious thermal stimuli. Across the range of doses tested, spiradoline and U50,488 
were more potent in males than females, and this effect was observed following both 
systemic and local administration at the site of inflammation. U69,593 was also more potent 
in males, although this effect was observed only following local administration. To date, only 
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two published studies have examined sex differences in κ opioids using persistent pain 
models. Clemente et al. (2004) reported that local administration of U50,488 was more 
effective at reducing formalin-induced hyperalgesia in female rats, with the magnitude of this 
effect being greater during diestrous than proestrous. Similarly, Binder et al. (2000) reported 
that the peripherally active κ-opioid asimadoline was more effective in female rats at 
reducing Freunds-induced hyperalgesia when tested against a thermal stimulus. Sex 
differences were not observed in this study when asimadoline was tested against a 
mechanical stimulus or with PNU50488H. Given that distinct mechanisms contribute to the 
persistent hyperalgesia induced by injections of formalin, Freunds and capsaicin (McCall et 
al. 1996, Holzer 1991, LeBars 2001), identifying the sexually-dimorphic action of κ opioids 
in these persistent pain models will require extensive investigation. However, the present 
study provides preliminary evidence to suggest marked sex differences in responsiveness to κ 
opioids and that the direction of these sex differences may be dependent upon the 
mechanisms underlying the different types of persistent nociception. 
The present finding that spiradoline, U50,488 and U69,593 were on average 147, 9.9 
and 57-fold more potent when administered locally than systemically, respectively, suggests 
that in both males and females the antihyperalgesia induced by local administration of κ 
opioids was mediated predominantly by activity in the site of inflammation (Ko et al. 1999). 
Local κ opioid activity was confirmed by the demonstration that in males and females local, 
but not i.c.v., administration of the κ-opioid antagonist nor-BNI attenuated the effects of 
local administration of both U69,593 and spiradoline. These data suggest that when 
administered locally U69,593 and spiradoline attenuated capsaicin-induced hyperalgesia 
actions via activity at peripheral κ opioid receptors. These findings extend previous studies 
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by demonstrating sex differences in κ opioid antihyperalgesia mediated by opioid activity at 
the site of inflammation. 
Several possible mechanisms have been demonstrated to account for the greater 
effectiveness of local administration of opioids in persistent pain models. For example, 
inflammation is associated with an increased expression of opioids receptors in the dorsal 
root ganglia and upregulation of opioid receptors in small primary afferent neurons (Ji et al. 
1995; Zollner et al. 2003). Inflammatory conditions can also disrupt the perineurial barrier, 
allowing for greater access of peripherally administered opioids to the opioid receptor 
population (Antonijevic et al. 1995). Although the present investigation did not directly 
compare these processes in males and females, the observation that κ opioids were effective 
when administered locally suggests that these peripheral processes are active in both males 
and females. Such findings are consistent with previous reports indicating that similar 
opioid/pain circuitry exists in males and females, but the characteristics of this circuitry can 
be altered by the gonadal hormones (e.g., Kavaliers and Galea 1995; Sternberg et al. 2004). 
As with U69,593 and spiradoline, sex differences were observed with U50,488. In 
contrast to these κ opioids, local administration of nor-BNI failed to attenuate the effects of 
U50,488. It is unlikely that the effects produced by local injections of U50,488 were 
mediated by activity at the µ receptor, as in this preparation µ opioids are slightly more 
potent in females (Barrett et al. 2003). Although considered a selective κ agonist, U50,488 
can produce antinociception by activating non-opioid receptor sites. For example, the 
antinociception produced by local injections of the (+)-enantiomer of U50,488 as well as 
high doses of the (-)-enantiomer are not reversed by nor-BNI (Joshi and Gebhart 2003). This 
antihyperalgesic effect is believed to be mediated by a direct blockade of sodium channels 
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and not activation of κ opioid receptors. The current findings contrast with those reported 
previously in capsaicin preparations. In rhesus monkeys local administration of nor-BNI 
antagonized the antihyperalgesic effects produced by U50,488 (Ko et al. 1999), and in rats 
the effects of U50,488 were reversed by doses of the opioid antagonist quadazocine 
considerably larger than those required to attenuate the effects of the µ agonist fentanyl (Ko 
et al. 2000). Although it is difficult to reconcile these findings, it does confirm that under 
some conditions the local antihyperalgesic actions of U50,488 are not mediated directly by 
activity at the κ opioid receptor.  
Recent studies suggest that sex differences in κ opioid antinociception may result 
from differential NMDA receptor activity. Indeed, NMDA antagonists selectively attenuate κ 
opioid antinociception in male and ovariectomized female mice and rats (e.g., Mogil et al. 
2003; Sternberg et al. 2004; Holtman and Wala 2006). Whether these sex-dependent effects 
are apparent in models of persistent pain have yet to be determined. In the present 
investigation, the NMDA antagonist dextromethorphan attenuated the antihyperalgesic effect 
of U69,593, spiradoline and U50,488, and this effect was observed in both males and 
females. In contrast, dextromethorphan attenuated the effects of U69,593 in the 50ºC warm 
water tail-withdrawal procedure only in males, a finding congruent with other studies using 
acute pain models (Kavaliers and Choleris 1997). Indeed, NMDA antagonists have been 
shown to selectively antagonize the effects of various κ opioids (e.g., U69,693, U50,488) in 
rats and mice using the warm water tail-withdrawal and tail-flick procedures (e.g., Mogil et 
al. 2003; Holtman and Wala 2006). Collectively, these findings provide evidence to suggest 
that the NMDA receptor system plays a critical role in mediating sex differences in the 
effects produced by κ opioids in acute but not persistent pain models. 
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Direct comparisons between the effects produced by κ opioids in acute and persistent 
pain models should be interpreted with caution. Hyperalgesia associated with persistent 
nociception can be distinguished from acute nociception in both the transmission of 
nociceptive information, presence vs absence of inflammation, type of nociceptive response, 
as well as the underlying neurochemical substrates (Le Bars et al. 2001; McCall et al. 1996). 
Even though in the present investigation the same type of nociceptive response (i.e., tail 
withdrawal from warm water) was utilized with capsaicin in the 50ºC warm water tail-
withdrawal procedure, there were still numerous procedural and parametric differences 
between these procedures. Moreover, in these procedures different doses of U69,593 were 
required to obtain maximal effects.  
With models of inflammation, like capsaicin, opioids can produce their effects via 
both local at the site of inflammation and central sites, whereas in acute models of pain the 
activity of opioids appears to be restricted to central sites (Yaksh 1997, LeBars 2001). As 
such, it was possible that the interaction between the NMDA and opioid systems could be 
apparent at both the central and local level. In the present investigation, systemic 
administration of dextromethorphan produced minimal attenuation of the antihyperalgesia 
induced by local administration on U69,593, which contrasts with the almost complete 
reversal observed following systemic administration of U69,593. A relatively high dose of 
dextromethorphan administered locally also failed to attenuate the antihyperalgesic effects of 
local administration of U69,593. These findings suggest that in some pain models, 
attenuation of κ opioid antihyperalgesia can only be obtained when both the NMDA 
antagonist and κ opioid are acting centrally.  
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An additional purpose of the present investigation was to examine the effects of 
mixed-action opioids with relatively low efficacy at κ receptors (e.g., Dykstra 1990; 
Butelman et al. 1998). Both butorphanol and nalbuphine were more potent when 
administered locally at the site of inflammation than systemically. The antihyperalgesia 
produced by nalbuphine was reversed by local administration of nor-BNI, establishing the 
contribution of κ opioid receptors at the site of inflammation. In contrast, the finding that 
nor-BNI failed to antagonize the antihyperalgesia produced by butorphanol suggests 
receptors other than κ receptors are involved in its antihyperalgesic effects. Despite the 
differential action of butorphanol and nalbuphine, sex differences were not observed in their 
antihyperalgesic effects. To some extent these findings contrast with previous studies 
indicating that sex differences with butorphanol and nalbuphine are typically larger that those 
observed with more efficacious opioids in both acute and persistent pain models (Cook et al. 
2000; Craft and Bernal 2001; Cook and Nickerson 2005). Although the effects of selective κ 
opioids have not been examined in humans, some studies do suggest that mixed-action 
opioids with κ opioids activity have greater antihyperalgesic effects in females (Craft 2003). 
The discrepancies across these studies may be a consequence of the type of pain model 
employed, suggesting further that the relative potency of opioids in males and females is 
specific to certain inflammatory pain models. The factors that make these models different 
may be critical in understanding sex differences in opioid antinociception.  
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Table 3.1 ED50 values (95% confidence limits) and  relative potency ratios (95% 
confidence limit) for male and female rats (n = 6–8) in tests conducted with spiradoline, 
U50,488, U69,593, butorphanol and nalbuphine when administered systemically (s.c.; 
mg/kg) and  locally (tail; µg). 
_________________________________________________________________________________________________________ 
 
Drug                      Males      Females   Potency Ratio 
_________________________________________________________________________________________________________ 
Spiradoline   
     Tail  0.019 (0.013-0.266) 0.028 (0.019-0.45)  1.84 (1.23-2.92)a
     SC  2.82 (1.41-5.64) 11.2 (4.58-27.2)  3.19 (1.57-14.85)a
 
U69,593 
     Tail  0.11 (0.09-0.14) 0.16 (0.11-0.22)  1.32 (0.94-1.88) 
     SC  6.92 (5.49-8.74) 6.5 (4.7-8.98)   0.88 (.609-1.24) 
 
U50,488 
     Tail  0.099 (0.068-0.15) 0.19 (0.14-0.28)  1.98 (1.11-4.05) a
     SC  0.30  (0.157-0.58) 4.36 (1.95-9.75)  18.6 (6.67-69.3) a
 
Butorphanol 
     Tail  0.031 (0.022-0.444) 0.05 (0.37-0.07)  1.51 (0.88-2.76) 
     SC  0.203 (0.087-0.486) 0.113 (.004-0.36)  1.48 (0.40-5.76) 
 
Nalbuphine 
     Tail  0.35 (0.28-0.44) 0.38 (0.31-0.45)  1.09 (0.82-1.49) 
     SC  7.86 (4.54-13.6) 3.05 (1.21-7.75)  1.91 (0.89-4.72)
__________________________________________________________________________________________________________
 
 a  More potent (P <.05) in males than females as determined by relative potency ratio. 
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Table 3.2 Relative potency ratios (95% confidence limit) for spiradoline, U50,488, 
U69,593, butorphanol and nalbuphine  when administered systemically (s.c.) and  
locally (tail) in male and female rats (n = 6-8).  
___________________________________________________________________________________________________ 
 
Drug   Males     Females   
___________________________________________________________________________________________________ 
Spiradoline  192.2 (102.8-364.8) a             102.0 (42.1 - 205.9) a
 
U50,488  3.30 (1.17-6.61) a   16.38 (7.032-74.1) a 
 
U69,593  69.23 (49.2-98.8)a   44.02 (26.1-71.5) a
  
Butorphanol  9.83 (4.01-27.9) a   3.15 (0.579-12.2) 
  
Nalbuphine  19.82 (11.7-34.0) a   11.54 (7.34 -17.4) a
__________________________________________________________________________________________________  
 
a  More potent (P <.05) when administered locally than systemically as     
   determined by relative potency ratio. 
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Figure 3.1 Antihyperalgesic effects of spiradoline, U50,488 and U69,593 administered 
systemically (s.c.) and locally (tail) in male and female rats (n=6-8). Data for systemically 
administered drugs are expressed in mg/kg and for locally administered drugs in µgs. A 
warm water tail-withdrawal procedure was used for testing in which the distal 7 cm of the tail 
was immersed in water maintained at 45oC. Equally effective doses of capsaicin were 
injected 3.5 cm from the tip of the tail 15 min prior to the test with all opioids administered at 
the same time as capsaicin. Vertical bars represent the standard error; where not indicated, 
the standard error fell within the data point. 
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Figure 3.2 Panels a and b. Antihyperalgesic effects of local (tail) administration of U69,593 
(300 µg) alone and in combination with central (i.c.v.) or local (tail) administration of nor-
BNI (10 µg) in male and female rats (n=5) in the capsaicin preparation. Additional details are 
as described in Fig. 1. Asterisks (*) indicate a significant difference between the 
antihyperalgesic effects of U69,593 alone (tail) vs in combination with nor-BNI (tail). 
Crosses (+) indicate a significant difference in the antihyperalgesic effect of the combination 
of U69,593 administered in the tail and nor-BNI administered i.c.v. vs to the combination of 
U69,593 and nor-BNI administered in the tail. Panels c and d. Antinociceptive effects of 
U69,593 alone when administered systemically (3.0 mg/kg males; 5.6 mg/kg females: these 
doses were determined to be equally effective in males and females) and in combination with 
central (i.c.v.) administration of nor-BNI (10 µg) in the warm water tail-withdrawal 
procedure in males and females. In this procedure, the distal 7 cm of the tail was immersed in 
water maintained at 50°C and latency to withdrawal the tail from warm water was recorded. 
Antinociceptive effects of U69,593  administered locally (tail; 300 µg) are also shown. All 
tests were conducted in male and female rats (n=5). For all panels, vertical bars represent the 
standard error; where not indicated, the standard error fell within the bar or the data point.  
Asterisks (*) indicate a significant difference in the antinociceptive effects of U69,593 alone 
(s.c.) vs in combination with nor-BNI (i.c.v.).  
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Figure 3.3 Antihyperalgesic effects of local (tail) injections of spiradoline (100 µg), U50,488 
(300 µg males, 1000 µg females: these doses were determined to be equally effective in 
males and females), alone and in combination with local injections of  nor-BNI (10 µg) in 
male and female rats (n=6-8) in the capsaicin preparation. Procedural details are as described 
in Fig. 1. Vertical bars represent the standard error; where not indicated, the standard error 
fell within the bar. Asterisks (*) indicate a significant difference between the 
antihyperalgesic effects of opioids alone vs in combination with nor-BNI.  
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Figure 3.4 Antihyperalgesic effects of the mixed-action opioids butorphanol and nalbuphine 
administered both systemically (s.c.) and locally (tail) in male and female rats (n=6-8) in the 
capsaicin preparation. Data for systemically administered drugs are expressed in mg/kg and 
for locally administered drugs in µgs. Other procedural details are as described in Fig. 1. 
Vertical bars represent the standard error; when not indicated, the standard error fell within 
the bar.  
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Figure 3.5 Antihyperalgesic effects of local (tail) administration of nalbuphine (1000 µg), 
butorphanol (100 µg males, 300 µg females: these doses were determined to be equally 
effective in males and females) alone and in combination with local (tail) administration of  
nor-BNI (10 µg) in male and female rats (n=6-8) in the capsaicin preparation. Procedural 
details are as described in Fig. 1. Vertical bars represent the standard error, where not 
indicated, the standard error fell within the bar. Asterisks (*) indicate a significant 
differences in the antihyperalgesic effect when the opioid was administered alone vs in 
combination with nor-BNI. 
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Figure 3.6 Antihyperalgesic effects of systemically (s.c.) administered U69,593 (10 mg/kg) 
alone and in combination with systemically (s.c.) administered dextromethorphan in male 
and female rats (n=6–8) in the capsaicin preparation. Procedural details are as described in 
Fig. 1.  Alone, dextromethorphan (3.0-30 mg/kg) had no antihyperalgesic effects (data not 
shown). Vertical bars represent the standard error; when not indicated, the standard error fell 
within the bar. Asterisks (*) indicate significant difference in the antihyperalgesic effects of 
U69,593 alone vs in combination with dextromethorphan. 
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Figure 3.7  Antihyperalgesic effects of U69,593 (300 µg) administered locally (tail), and in 
combination with dextromethorphan (30 mg/kg) administered systemically (s.c.) and locally 
(tail) in the capsaicin preparation in male and female rats (n=6–8). Procedural details are as 
described in Fig. 1. Vertical bars represent the standard error; when not indicated, the 
standard error fell within the bar. Asterisks (*) indicate significant difference in the 
antihyperalgesic effects of local administration of U69,593 alone vs in combination with 
dextromethorphan administered systemically. 
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Figure 3.8 Antihyperalgesic effects of spiradoline (17.5 mg/kg) and U50,488 (10 mg/kg, 
males; 17.5 mg/kg, females: these doses were determined to be equally effective in males and 
females) alone and in combination with dextromethorphan (30 mg/kg) in male and female 
rats (n=6–8) in the capsaicin preparation. Procedural details are as described in Fig. 1. All 
drugs were administered systemically (s.c.). Vertical bars represent the standard error; where 
not indicated, the standard error fell within the bar. Asterisks (*) indicate significant 
difference in the antihyperalgesic effects of opioid alone vs in combination with 
dextromethorphan. 
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Figure 3.9 Panel A. Antinociceptive effects of U69,593 (3.0 mg/kg males; 5.6 mg/kg 
females: these doses were determined to be equally effective in males and females) alone and 
in combination with dextromethorphan (30 mg/kg) when administered systemically (s.c.) in 
both male and female rats (n=6-8) in the warm water tail-withdrawal procedure. Vertical bars 
represent the standard error; where not indicated, the standard error fell within the data point. 
Panel B. Area under the curve (AUC) difference score for systemic administration of 
U69,593 in combination with dextromethorphan. Data represent the difference in AUC for 
U69,593 alone - AUC for U69,593 in combination with dextromethorphan in both males and 
females. Asterisks (*) indicate a significant sex difference in AUC difference score. 
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CHAPTER 4 
SEX DIFFERENCES IN NMDA ANTAGONIST ENHANCEMENT OF 
MORPHINE ANTIHYPERALGESIA IN A CAPSAICIN MODEL OF 
PERSISTENT PAIN: COMPARISONS TO TWO MODELS OF ACUTE PAIN  
 
Introduction 
Sex differences in opioid antinociception have been studied extensively in acute pain 
models (e.g., hotplate), with the majority of reports indicating that male rodents and monkeys 
are more sensitive to the antinociceptive effects of µ opioids than their female counterparts 
(Negus and Mello, 1999; Cook et al., 2000; Craft and Bernal, 2001). Several recent lines of 
physiological, pharmacological and behavioral evidence suggest that this sexual dimorphism 
may extend to the manner in which NMDA antagonists modulate the actions of µ opioids. 
For example, dizocilpine has been shown to reduce morphine-induced c-Fos expression to a 
greater extent in female rats, with castrated males displaying a level of c-Fos expression 
similar to that of females (D’Souza et al., 1999; D’Souza et al., 2002). In a hotplate 
procedure, dizocilpine selectively blocks the development of morphine tolerance in male 
mice, whereas in a warm water tail-withdrawal procedure it selectively facilitates the 
development of tolerance in males (Bryant et al. 2006). Of particular clinical relevance is the 
finding that NMDA antagonists produce a sexually-dimorphic effect on acute µ opioid 
antinociception. Indeed, Grisel et al. (2005) reported that dextromethorphan enhanced 
morphine antinociception in male and ovarectomized female mice, but attenuated morphine 
antinociception in intact females. Similarly, Craft and Lee (2005) reported that 
dextromethorphan enhanced morphine antinociception to a greater extent in male rats, with 
this effect being most evident in a hotplate procedure. Not all reports indicate that NMDA 
antagonists produce sexually-dimorphic effects on morphine antinociception (e.g., Bryant et 
al., 2006; Holtman et al., 2003), with these discrepancies most likely explained by 
differences across studies in type of NMDA antagonist, dose of NMDA antagonist, 
procedure, and rodent genotype. The dose of morphine tested is also critical, as some NMDA 
antagonists enhance low levels of antinociception produced by morphine and attenuate high 
levels (Nemmani et al., 2004; Craft and Lee, 2005). 
In contrast to these findings in acute pain models, there are no investigations 
evaluating sex differences in NMDA-opioid interactions using persistent pain models. 
Nociception induced by persistent and acute nociception differ along a number of critical 
dimensions, including their neurochemical and anatomical substrates, duration, frequency, 
and type of nociceptive response, as well as the type of nociceptive fibers they activate 
(LaMotte et al. 1992; McCall et al. 1996; Le Bars et al. 2001; Kayser et al 2007). The distinct 
mechanisms underlying acute vs persistent pain have been shown to be critical determinants 
of sex differences in both opioid sensitivity and NMDA-opioid interactions. Indeed, recent 
studies suggest that the sex differences in µ opioid antinociception apparent in acute pain 
models may not be apparent in all persistent pain models (Barrett et al, 2003: Cook and 
Nickerson, 2004). Moreover, NMDA antagonists have been shown to selectively block the 
antinociceptive effects κ opioids in males when examined in various models of acute pain, 
but not in models of persistent pain (Mogil et al., 2003; Holtman and Wala, 2006; Lomas et 
al., 2007). Clearly, while acute nociceptive assays are a beneficial starting point, it is 
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essential to determine if the sexually-dimorphic manner in which NMDA antagonists 
modulate the effects opioids is apparent in persistent pain models. 
The purpose of the present study was to examine sex differences in the extent to 
which the NMDA antagonist dextromethorphan alters the antihyperalgesic effects of 
morphine in a model of persistent pain. In the model selected for study, the chemical irritant 
capsaicin was administered directly into the tail resulting in inflammation, vasodilatation and 
a hyperalgesic response localized at the site of administration (Caterina et al., 1997; Holzer et 
al., 1991; Winter et al., 1995). The hyperalgesia induced by capsaicin was then measured by 
a decrease in the latency to tail-withdrawal from an acute presentation of a mildly noxious 
thermal stimulus (45oC water), and in both males and females this hyperalgesia persists for 
60-90 mins (Barrett et al., 2003). Unlike some models used to examine persistent pain (e.g., 
formalin-induced hyperalgesia), in the capsaicin procedure NMDA antagonists do not alter 
the development or persistence of the hyperalgesic response (Sakurada et al., 1998; Lomas et 
al., 2007). As such, this model provides a unique opportunity to examine sex differences in  
NMDA-opioid interactions against a persistent form of nociception. In order to facilitate 
comparisons across studies, as well as provide a direct comparison across acute and 
persistent pain models using the same drugs, doses and rodent strain, tests were also 
conducted using a hotplate (52oC) and warm-water tail-withdrawal (52oC) procedure.  
 
Methods 
Animals  
Intact male and female F344 rats were obtained from Charles River Laboratories 
(Raleigh, NC, USA).  All testing occurred between 3 and 6 months of age, and rats were 
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individually housed in a colony on a 12-h/12-h light/dark cycle.  All rats had unlimited 
access to food and water. 
 
Testing 
Capsaicin: A warm-water tail withdrawal procedure was used to assess hyperalgesia 
induced by an injection of capsaicin in the tail. During testing, each rat was lightly restrained, 
with the distal 7 cm of the tail immersed in water maintained at 45oC, a relatively innocuous 
nociceptive stimulus (Lynn and Carpenter, 1982).  Baseline tail-withdrawal latencies were 
determined before administration of any drugs, and rats that failed to maintain their tails in 
the water for 15 sec were excluded from subsequent testing. Following determination of 
baseline latencies, capsaicin was injected 3.5 cm from the tip of the tail. All injections of 
capsaicin were made under light halothane anesthesia, with rats recovering from this 
procedure within 2-3 mins. After administration of capsaicin, tail-withdrawal latencies 
decreased from 15 sec to an average of  3.5 - 4.5 sec with this effect being comparable in 
both males and females.  
For tests of the antihyperalgesic effects of morphine and dextromethorphan, a 3.0 and 
1.0 µg dose of capsaicin was chosen for males and females, respectively, as these doses 
produce a comparable magnitude and duration of hyperalgesia (Barrett et al., 2003). Before 
initiating testing, a capsaicin baseline was assessed in each rat. Approximately 1 week later, 
capsaicin was administered in the tail, followed by an intraperitoneal (i.p) injection of saline, 
morphine or dextromethorphan alone or in selected combinations. Dextromethorphan was 
chosen as it is used clinically and has previously been shown to enhance morphine 
antinociception in a number of acute nociceptive procedures (Grisel et al., 2005; Pleasan et al 
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1995). Although a number of pretreatment times and doses were examined for both 
dextromethorphan and morphine, tail-withdrawal latencies were always determined 15 min 
after the capsaicin tail injection, which is the time point corresponding to the peak effect of 
capsaicin. For all tests, a 15 sec cutoff latency was implemented, as this indicated a maximal 
antihyperalgesic effect (i.e., nociceptive thresholds returned to baseline levels). Rats were 
tested approximately once per week with no more than 5 tests per animal. Previous studies 
conducted in our laboratory indicated that this frequency of testing and the number of tests 
produced reliable and consistent tail-withdrawal latencies (Barrett et al., 2003).  
Warm water tail-withdrawal and hotplate procedures: Prior to testing, rats were 
habituated to restraint tubes, baseline tests were conducted in both the warm water tail-
withdrawal and hotplate procedures, and each rat was administered a 2.5 mg/kg dose of 
morphine (no data were collected for this test). This habituation protocol was designed, in 
part, to limit the impact of stress-induced antinociception which has previously been reported 
to be influenced by sex but minimized by habituation (Mogil and Belknap, 1997; Dhabhar et 
al., 1997).  
During both habituation and testing in the warm water tail-withdrawal procedure, rats 
were placed in restraint tubes, the distal 7 cm of the tail immersed in 52oC water, and the 
latency to tail-withdrawal  recorded. An increase in the latency to remove the tail from the 
warm water was taken as a measure of nociception, with an upper cutoff limit of 15 sec to 
minimize tissue damage. In this procedure, baseline tail-withdrawal procedures ranged from 
7-10 sec in males and 6.5-9 sec in females. After a baseline tail-withdrawal latency was 
determined, rats were placed on the hotplate which was set at 52oC. Latency to hind-paw lick 
or an escape response was then determined, with an upper cutoff time of 60 sec. In this 
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procedure, baseline to hind-paw lick or an escape latencies ranged from 20-35 sec in males 
and 17-35 sec in females. In each series of tests, two baseline latencies were determined prior 
to drug administration. Subsequently, rats were administered an i.p injection of saline, 
morphine and dextromethorphan alone or in selected combinations. Data for both the warm 
water tail-withdrawal and hotplate procedures were collected across a 2 hr interval. No rat 
was exposed to the testing procedures more than 6 times and at least 6 days separated each 
test. 
 
Data Analysis 
Capsaicin: For the antihyperalgesic effects of drugs, latencies to tail-withdrawal 
following administration of drug were converted to the percentage of the maximum possible 
effect using the following equation: % antihyperalgesic effect = [(observed-baseline)/(15 s-
baseline)] x 100.  An ANOVA analysis was then used to determine differences across 
dose/drug combinations and sex. In instances in which there was a main effect for drug 
condition and sex, post-hoc tests were conducted using the Fisher’s protected least significant 
difference test to compare dose combinations within sex. For statistical analyses, the alpha 
level was set at 0.05. The dose of morphine required to produce a 50% antihyperalgesic 
effect (ED50) was derived mathematically (least-squares method) using log-linear 
interpolation with at least three doses on the ascending limb of the dose-effect curve.  
 
Warm water tail-withdrawal and hotplate procedures: In order to calculate % 
maximal antinociceptive effects, tail-withdrawal latencies (warm water) and lick/escape 
latencies (hotplate) were converted to percent antinociceptive effect using the following 
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equation: % antinociceptive effect = [(test latency - baseline) / (cutoff - baseline)] X 100. The 
time-course evaluation of a drug effects was measured in these procedures and thus area 
under the curve was used for statistical analysis. Area under the curve was estimated by the 
Trapezoidal Rule using available statistical software (Tallarida and Murray 1987®). An 
ANOVA analysis was then used to determine differences across doses and sexes. Post hoc 
tests and ED50 values were calculated in a manner similar to that described above. For 
statistical analyses, the alpha level was set at 0.05.   
 
Drugs 
The following drugs were used: morphine sulfate (provided by the National Institute 
on Drug Abuse), dextromethorphan hydrobromide monohydrate, and capsaicin (both 
purchased from Sigma-Aldrich Co., St. Louis, Mo.). Capsaicin was dissolved in a solution of 
Tween 80 / 95% ethanol / saline in a ratio of 1/1/8, and was diluted to lower concentrations 
with saline. Capsaicin was injected alone in the tail in a 0.1-ml volume. Saline, morphine and 
dextromethorphan were administered i.p. in a volume of 0.5 to 1.0 ml/kg. Small amounts of 
lactic acid were added to dextromethorphan to promote solubility.  As dextromethorphan 
occasionnally caused lesions and severe adverse effects in both male and female rats at the 
30 mg/kg dose, testing at this dose was limited.  
 
Results 
Fig. 1 shows that in males and females morphine produced dose-dependent increases 
in antihyperalgesia, with near maximal effects obtained at the highest dose tested. ANOVA 
indicated a main effect for dose (F4,64=26.9, P<0.05), no main effect for sex, or a dose x sex 
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interaction.  ED50 values for morphine in females 6.22 mg/kg (95% CL: 3.95-9.79) and males 
4.45 mg/kg (95% CL: 2.57-7.86) were also similar. Across the dose range examined, 
dextromethorphan produced only minimal levels of antihyperalgesia in both males and 
females, with no dose tested producing greater than an 11% effect. The higher doses of 
dextromethorphan did, however, produce sedation and disruption of motor performance, 
although these effects were typically short lived and did not interfere with testing. 
Fig. 2 shows that in males dextromethorphan enhanced the antihyperalgesic effect of 
doses of morphine that produced minimal (1.0 and 2.5 mg/kg) to moderate (5.0 mg/kg) 
antihyperalgesic effects when administered alone. At the two lowest doses of morphine 
tested, 20 and 30 mg/kg dextromethorphan increased the antihyperalgesic effect of morphine 
from 11% to 74%, and from 13% to 86%, respectively. At the highest dose of morphine 
tested, 10 mg/kg dextromethorphan increased levels of antihyperalgesia from 73% to 100%. 
In females, no dose of dextromethorphan altered the antihyperalgesic effects produced by 
morphine. For 1.0 and 2.5 mg/kg morphine, ANOVA confirmed a main effect for sex (1.0: 
F1,48=12.5, P<0.05; 2.5: F1,41=64.6, P<0.05), drug (1.0: F3,48=13.9, P<0.05; 2.5: F3,41=8.69, 
P<0.05), and a sex x drug interaction (1.0: F3,48=6.4, P<0.05; 2.5: F3,41=6.45, P<0.05). At 5.0 
mg/kg morphine, ANOVA indicated a main effect for sex, (F1,32=7.57, P<0.05), but no main 
effect for drug and no sex x drug interaction. Post hoc tests confirmed that, with the 
exception of 1.0 mg/kg morphine / 10 mg/kg dextromethorphan combination, in males all 
dose combinations enhanced (P<0.05) the antihyperalgesic effect of morphine. In contrast, 
enhancement of the antihyperalgesic effects of morphine was not obtained in females 
regardless of the dose combination tested. 
 75
In order to determine if these sex-specific effects of dextromethorphan were a 
consequence of a sexual dimorphism in the time-course of morphine or dextromethorphan 
actions, tests were conducted in which selected doses of these drugs were administered at 
different pretreatment times. Fig. 3 shows that in males dextromethorphan enhanced the 
antihyperalgesic effect of morphine at all pretreatment times tested. In females, varying the 
pretreatment time of dextromethorphan failed to alter the antihyperalgesic effectiveness of 
morphine. ANOVA confirmed a main effect for sex (F1,48=97.3, P<0.05), pretreatment time 
(F3,48=9.106, P<0.05), and a sex x pretreatment time interaction (F4,48=9.75, P<0.05). Post 
hoc tests also confirmed enhancement (P<0.05) of the antihyperalgesic effect of morphine at 
all dextromethorphan pretreatment times in males, but at no pretreatment time in females. 
Fig 4 shows the antihyperalgesic effect of morphine when administered at various 
pretreatment times before dextromethorphan. For males, all pretreatment times produced an 
enhancement of morphine antihyperalgesia, whereas in females enhancement was not 
observed at any pretreatment time. ANOVA confirmed a main effect for sex (F1,66= 55.6, 
P<0.05), pretreatment time (F4,66=2.8, P<0.05), and a sex x pretreatment time interaction 
(F4,66=9.7, P<0.05). Post hoc tests confirmed an enhancement (P<0.05) of the 
antihyperalgesic effect of morphine at all dextromethorphan pretreatment times in males, 
whereas in females enhancement was not observed at any pretreatment time. 
Fig. 5 shows the effects of morphine and dextromethorphan alone in males and 
females in two acute pain models, the warm water tail-withdrawal and hotplate procedures. 
Across the dose range examined, dextromethorphan failed to produce an antinociceptive 
effect. Alone, morphine produced dose-dependent increases in antinociception in both males 
and females. Based on morphine ED50 values in females (6.47 mg/kg, 95% CL: 4.87-8.60) 
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and males (6.03 mg/kg, 95% CL: 5.08-7.17) there were no sex differences in the potency of 
morphine in the warm water tail-withdrawal procedure. Time-course analyses of morphine 
(2.5 - 10 mg/kg morphine) in males and females (data not shown) indicated that the peak 
effects of morphine were typically seen at the 30 min test interval, and thereafter the 
magnitude of morphine antinociception gradually decreased, returning to baseline levels 
between 90 and 120 mins. ANOVA of these time-course data indicated no main effect for 
sex, a main effect for dose (F3,43= 41.2, P<0.05) with no dose x sex interaction. Similarly, in 
the hotplate procedure sex differences were not observed in the potency of morphine, as 
comparable  ED50 values were obtained in females (12.36 mg/kg, 95% CL: 5.69-26.9) and 
males (8.06 mg/kg, 95% CL: 5.74-11.3). Peak effect and the duration of morphine (2.5 - 10 
mg/kg) antinociception in this procedure were similar to that observed in the warm water tail-
withdrawal procedure (data not shown). ANOVA of these time-course data  indicated no 
main effect for sex, a main effect for dose (F3,44= 13.5, P<0.05) with no dose x sex 
interaction. 
Fig. 6 shows the antinociceptive effect of selected doses of morphine when combined 
with dextromethorphan in the warm water tail-withdrawal procedure. Alone, in both males 
and females 2.5 and 5.0 mg/kg morphine produced only low levels of antinociception (less 
than 24%). When administered in combination, dextromethorphan produced a dose- and 
time-dependent enhancement of morphine antinociception, with this effect observed in both 
males and females. At the higher doses of dextromethorphan, morphine produced near 
maximal levels of antinociception with a peak effect and duration of action that was 
consistently larger in males. When enhancement was observed in males, low to moderate 
levels of antinociception were generally apparent even at the 120 min test interval. In 
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contrast, in females antinociception was not typically observed beyond the 60 or 90 min test 
intervals. ANOVA of area under the curve data for 2.5 and 5.0 mg/kg morphine indicated a 
main effect for sex (2.5: F1,65=39.4, P<0.05; 5.0: F1,49=6.78, P<0.05), drug (2.5: F4,65=23.3, 
P<0.05; 5.0: F3,49=22.3, P<0.05), and a sex x drug interaction (2.5: F4,65=3.13, P<0.05; 5.0: 
F3,49=4.12, P<0.05).  
Post hoc tests conducted on AUC data revealed that in males 5.0 and 10 mg/kg 
dextromethorphan were the lowest doses that enhanced (P>0.05) the effects produced by 2.5 
and 5.0 mg/kg morphine, respectively. In females, enhancement of morphine antinociception 
was observed at the 20 and 10 mg/kg dextromethorphan doses, respectively. These analyses 
also confirmed a significantly (P<0.05) larger antinociceptive effect in males for all doses of 
dextromethorphan in combination with 2.5 mg/kg morphine and at the two highest doses of 
dextromethorphan in combination with 5.0 mg/kg morphine. 
 Similar effects were obtained in the hotplate procedure. Alone, both doses of 
morphine produced only low levels of antinociception, less than 11% in males and 15% in 
females. As shown in Fig. 7, the antinociceptive effects of morphine were enhanced by the 
two higher doses of dextromethorphan in males, and only at the highest dose in females. This 
effect was evident both in terms of the peak effect and duration of morphine antinociception. 
For both doses of morphine, ANOVA of area under the curve data indicated a main effect for 
sex  (2.5: F1,65=13.9, P<0.05; 5.0: F1,51= 7.45, P<0.05) and drug (2.5: F4,65=14.8, P<0.05; 
5.0: F3,51=7.7, P<0.05). A sex x drug condition interaction was evident only at 2.5 mg/kg 
morphine (F4,65=5.98, P<0.05).  Post hoc tests confirmed that the two highest doses of 
dextromethorphan enhanced the antinociceptive effect of both 2.5 and 5.0 mg/kg morphine to 
a greater extent (P<0.05) in males. For both doses of morphine, enhancement of morphine 
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antinociception was observed at the two highest doses of dextromethorphan in males, and 
only at the highest of dextromethorphan in females. 
 
Discussion  
One purpose of the present investigation was to examine the effects of the non-
competitive NMDA antagonist dextromethorphan on morphine antinociception in two acute 
pain models, the hotplate (52oC) and warm water tail-withdrawal (52oC) procedures. The 
failure to observe sex differences in morphine antinociception in these procedures provided 
an opportunity to evaluate potential interactions with NMDA antagonists under conditions in 
which baseline levels of morphine antinociception were comparable in both males and 
females. Under these conditions, dextromethorphan produced a dose- and time-dependent 
enhancement of morphine antinociception, with this effect observed in both males and 
females. In a number of instances, the combination of dextromethorphan and low doses of 
morphine produced maximal antinociceptive effects. The magnitude of these 
dextromethorphan-induced enhancements of morphine antinociception, however, was 
consistently larger in males and observed at lower doses of dextromethorphan. Such finding 
are consistent with previous studies indicating that in acute pain models NMDA antagonists 
enhance the peak effect and duration of morphine antinociception in both rats and mice 
(Grisel et al 2005, Nemmani et al., 2004, Craft and Lee, 2005). These findings extend those 
reports to a strain of rats (F344) known to display large sex differences in µ opioid 
antinociception (Terner et al. 2003), and confirm findings indicating that dextromethorphan 
can produce relatively large increases in morphine antinociception (e.g., Plesan et al. 1999). 
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In the hotplate procedure, the enhancement observed in male and female rats was 
smaller than that observed in the warm-water tail-withdrawal procedure.  These findings 
extend previous reports of differences across acute nociceptive assays in the extent to which 
NMDA antagonists enhance morphine antinociception. For example, Craft and Lee (2005) 
reported greater enhancement in male Sprague-Dawley rats in a hotplate procedure, yet failed 
to observe enhancement in a warm water tail-withdrawal procedure. Although greater effects 
were observed in the present investigation in the warm water tail-withdrawal procedure with 
F344 rats, this discrepancy could reflect a rodent strain-dependency, and there is evidence 
that rat strain and substrain are critical determinants of sensitivity to µ opioid antinociception 
(Terner et al., 2003, Kest et al., 1999), sex differences in µ opioid antinociception (Terner et 
al., 2003, Kest et al., 1999), and the extent to which dextromethorphan enhances the 
antinociceptive effects of µ opioids in males (Bulka et al, 2002, Plesan et al. 1999).  
The major purpose of the current investigation was to evaluate NMDA-opioid 
interactions in a model of persistent pain. In the procedure selected for study, administration 
of the chemical irritant capsaicin in the tail produces a 60-90 min hyperalgesic response to 
mildly noxious warm water (45oC). In this procedure, systemically administered morphine 
was equally potent at reducing capsaicin-induced antihyperalgesia in males and females 
(Barrett et al., 2003). Dextromethorphan, which had no antihyperalgesic effect when 
administered alone, produced a dose-dependent enhancement of morphine antihyperalgesia 
in males. The higher doses of dextromethorphan tested increased morphine antihyperalgesia 
by 63 - 73%. In contrast, in females dextromethorphan failed to enhance the antihyperalgesic 
effect of morphine. This sexually-dimorphic effect was observed across doses of morphine 
that produced both low and moderate levels of morphine antihyperalgesia. Such findings 
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markedly contrast with those reported in acute pain models, where enhancement is typically 
observed in both males and females (Craft and Lee, 2005; Grisel et al 2005; present 
investigation).  
While studies suggest that sex differences in µ opioid antinociception are not due to 
opioid pharmacokinetics, binding affinity, receptor density or µ receptor-stimulated 
[35S]GTPγS binding (Kepler et al., 1991; Candido et al., 1992; Cicero et al., 1996; Selley et 
al., 2003), some studies suggest a longer onset and shorter offset of morphine antinociception 
in females (Sarton et al, 2000). Moreover, some NMDA antagonists and their major 
metabolites have a longer plasma half-life in female rats (e.g., Ramachander et al., 1978; 
Shelnutt et al., 1999). Consequently, it was possible that the failure to observe enhancement 
in females was a consequence of the time-course of the drugs examined. To evaluate this 
possibility, pretreatment times ranging from 15 - 60 mins for both morphine and 
dextromethorphan were examined. Across the pretreatment times examined, 
dextromethorphan-induced enhancement of morphine antihyperalgesia was observed only in 
males. These findings suggest that the sexual dimorphism in NMDA-opioid interactions 
observed in the present investigation was not a consequence of sex differences in the 
pharmacokinetics of dextromethorphan or morphine, but rather reflects sex differences in the 
extent to which the NMDA system modulates the effects produced by µ opioids.  
The mechanism underlying this sexual dimorphism in NMDA-opioid interactions and 
why differences are more pronounced in models of persistent than acute pain have not been 
determined. Previous studies have shown a sex-dependency in NMDA-κ opioid interactions 
that is apparent in acute but not persistent pain models (Holtman and Wala, 2006; Lomas et 
al., 2007). Moreover, a sex-dependency in NMDA-µ opioid interactions have been observed 
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in stress-induced analgesia (e.g., Mogil et al 1993), the development of morphine tolerance 
(Bryant et al. 2006) and morphine-induced c-Fos expression (D’Souza et al., 1999; D’Souza 
et al., 2002). Some evidence also suggests that these sex-dependent effects may be mediated 
by estrogen, as estrogen can modulate NMDA receptors in various brain regions (Cyr et al., 
2001).  
Although the present investigation represents a preliminary investigation of NMDA-
opioids interactions in a persistent pain model, a weakness in our approach was the failure to 
determine estrous cycle or the potential influence of gonadal hormones. Indeed, the recent 
finding that the level of dextromethorphan-induced enhancement of morphine 
antinociception in ovarectomized female mice was comparable to that of male mice suggests 
that gonadal hormones may play a role in mediating NMDA-opioid interactions (Grisel et al 
2005). This finding is supported by evidence that female rats in diestrous show a greater 
enhancement of morphine antinociception by the NMDA antagonist LY235959 than in other 
estrous phases (Craft and Lee, 2005). Moreover, estrous cycle has been shown to influence 
the development of nociception in a variety of pain models (Aloisi and Ceccarelli, 2000; Ren 
et al., 2000), including the capsaicin procedure (Barrett et al., 2003). Given the pervasive 
nature of the influence of gonadal hormones on both nociception and opioid activity, it would 
not be surprising if gonadal  hormones influenced NMDA-opioid interactions in persistent 
pain models.  
It is well established that categorization of pain as being either acute or persistent 
represents an oversimplified construct. Numerous types of persistent pain have been well 
characterized (e.g., inflammatory, neuropathic), with each type mediated by distinct  
neurochemical substrates. For example, whereas activation of non-NMDA excitatory amino 
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acid receptors modulate the development and persistence of nociception in a plantar incision 
model of pain (Zahn et, 1998), NMDA receptors are involved in the hyperalgesia induced by 
Freund’s adjuvant and formalin (e.g., Ren and Dubner, 1993) as well as that produced by 
following neuropathic injuries (Mao et al, 1992). In contrast, capsaicin-induced hyperalgesia 
involves activation of neuorokinin receptors, but not NDMA receptors (Lao et al. 2003). As 
such, it is possible that the sexually dimorphic manner in which NMDA antagonists enhance 
µ opioid antihyperalgesia may be specific to certain pain models, and thus to certain types of 
pain. While it is important to examine the effects of the combination of NMDA antagonists 
and morphine in multiple persistent pain models, such experiments may prove difficult as 
NMDA antagonists can have a direct effect on the development of nociception. The lack of 
NMDA involvement in the development of the hyperalgesic response in the capsaicin model 
made this an effective model in which to initiate study of the effects of NMDA antagonist on 
µ opioid antihyperalgesia.  
While acute pain models represent a beneficial starting point to examine the effects of 
NMDA antagonists on µ opioid antinociception, ultimately in the clinical population these 
drugs will be used in conditions of persistent or chronic pain. In clinical studies, the extent to 
which NMDA antagonists enhance the analgesic effects of opioids has produced mixed 
results (e.g., Dudgeon et al., 2007).  For example, in cancer pain patients titrating doses of 
morphine or morphine/dextromethorphan combinations, the combination therapy provided 
satisfactory pain control at half the morphine dose (Katz et al, 2000). In contrast, in patients 
with chronic, non-neuropathic pain (e.g., low back pain, osteoarthritis), enhancement was not 
observed (Galer et al., 2005). The current findings may help explain some of these discrepant 
findings as they demonstrate that NMDA-opioid interactions are dependent upon the type of 
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nociception as well as the sex of the subject. Although sex has not been systematically 
examined in clinical studies, a recent set of case reports indicated that the NMDA antagonist 
ketamine was more effective in enhancing opioid analgesia in 2 male chronic pain patients 
then in a female patient  (Bell, 1999).  Determining the mechanism by which sex and the type 
of persistent pain mediate NMDA-opioid interactions should shed light on the potential 
clinical utility of combining NMDA antagonists with µ opioids.  
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Figure 4.1 Antihyperalgesic effects of morphine and dextromethorphan administered 
systemically  in male and female rats (n=6-8). A warm water tail-withdrawal procedure was 
used for testing in which the distal 7 cm of the tail was immersed in water maintained at 
45oC. Equally effective doses of capsaicin were injected 3.5 cm from the tip of the tail 15 
min prior to the test with all drugs administered at the same time as capsaicin. Vertical bars 
represent the standard error; where not indicated, the standard error fell within the data point. 
Asterisks (*) indicate significant difference in the antihyperalgesic effects of morphine alone 
vs in combination with selected doses of dextromethorphan. 
 
 
Dose (mg/kg)
Sal 1 3 10 30
%
 A
ni
th
yp
er
al
ge
si
c 
Ef
fe
ct
0
20
40
60
80
100
Morphine Morphine
Dex Dex 
Males Females
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85
Figure 4.2 Antihyperalgesic effects of morphine alone and in combination with 
dextromethorphan in male and female rats (n=6–8) in the capsaicin-induced hyperalgesia 
procedure. Procedural details are as described in Fig. 1.  Vertical bars represent the standard 
error; when not indicated, the standard error fell within the bar. Asterisks (*) indicate 
significant difference in the antihyperalgesic effects of morphine alone vs in combination 
with selected doses of dextromethorphan. 
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Figure 4.3 Antihyperalgesic effects of morphine alone and in combination with  a 
dextromethorphan in male and female rats (n=6–8) in the capsaicin-induced hyperalgesia 
procedure. The dose combination of morphine and dextromethorphan were selected as they 
produced high levels of antihyperalgesia in males (see Fig. 2). Dextromethorphan was 
administered at various pretreatment times before testing, while morphine was always 
administered 30 min before testing. Additional procedural details are as described in Fig. 1. 
Vertical bars represent the standard error; when not indicated, the standard error fell within 
the bar. Asterisks (*) indicate significant difference in the antihyperalgesic effects of 
morphine alone vs in combination with dextromethorphan. 
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Figure 4.4 Antihyperalgesic effects of morphine alone and in combination with  
dextromethorphan in male and female rats (n=6–8) in the capsaicin-induced hyperalgesia 
procedure. The dose combination of morphine and dextromethorphan were selected as they 
produced high levels of antihyperalgesia in males (see Fig. 2). Morphine was administered at 
various pretreatment times before testing, while dextromethorphan was always administered 
30 min before testing. Additional procedural details are as described in Fig. 1. Vertical bars 
represent the standard error; when not indicated, the standard error fell within the bar. 
Asterisks (*) indicate significant difference in the antihyperalgesic effects of morphine alone 
vs in combination with dextromethorphan. 
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Figure 4.5 Antinociceptive effects of morphine and dextromethorphan administered 
systemically in male and female rats (n=6-8) in a warm water tail-withdrawal procedure (left 
panel) and a hotplate procedure (right panel). All data reflect the effects of these drugs at a 30 
min pre-session injection time. In the warm water tail-withdrawal procedure, the distal 7 cm 
of the tail was immersed in water maintained at 52°C and latency to withdrawal the tail from 
warm water was recorded. In the hotplate procedure rats were placed on the 52°C hotplate 
and latency to hind paw withdrawal/escape was recorded. Control data (SAL) indicate the 
effects of saline administration. Vertical bars represent the standard error; where not 
indicated, the standard error fell within the data point. 
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Figure 4.6 Time-course assessment of the antinociceptive effects of selected doses of 
morphine administered alone (dotted lines) and in combination with dextromethorphan in 
female and male rats (n=6-8) in a warm water tail-withdrawal (52oC) procedure. Vertical bars 
represent the standard error; where not indicated, the standard error fell within the data point. 
Data in the right most panels reflect area under the curve (AUC) analyses for administration 
of morphine alone and in combination with dextromethorphan over 2 hr time course. 
Asterisks (*) indicate a significant sex difference in AUC. 
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Figure 4.7 Time-course assessment of the antinociceptive effects of selected doses of 
morphine administered alone (dotted lines) and in combination with dextromethorphan in 
female and male rats (n=6-8) in a hotplate (52oC) procedure. Vertical bars represent the 
standard error; where not indicated, the standard error fell within the data point. Data in the 
right most panels reflect area under the curve (AUC) analyses for administration of morphine 
alone and  in combination with dextromethorphan over 2 hr time course. Asterisks (*) 
indicate a significant sex difference in AUC. 
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CHAPTER 5 
GENERAL DISSCUSION 
 
Experimental Results 
The present series of experiments examined several factors that effect the direction 
and magnitude of sex differences in opioid antinociception, with a particular focus on the 
role of the modulatory actions of the NMDA system. Experiment 1 utilized a behavioral 
procedure to induce temporal summation of pain in rats. This short-lasting change in 
nociceptive sensitivity has been used as a model to examine the mechanisms underlying the 
development and persistence of chronic pain. In the current research, this model of temporal 
summation was evaluated for its sensitivity to parametric manipulations, sex differences, 
modulation by NMDA receptor antagonists, and sensitivity to reversal by opioids. The 
findings suggest a number of similarities in the characteristics and receptor modulation of 
temporal summation in humans and rats. Interestingly, in this model of chronic pain there 
were no sex differences in opioid potency. While this finding is consistent with those 
observed in some chronic pain models, it contrasts with those observed in acute pain models. 
Results also showed that the NMDA system played a modulatory role in the development of 
temporal summation, as pretreatment with selected NMDA antagonists greatly reduced the 
development of hypersensitivity to the nociceptive stimulus. 
Sex differences in the potency of the antinociceptive effects of both κ and µ opioids 
have been reported in acute pain models using thermal, chemical and mechanical nociceptive 
stimuli  (Kelpler et al. 1989; Cicero et al 1996, 1997; Barrett et al. 2002). Importantly, the 
majority of studies suggest that the sex differences observed in these models may be 
mediated by activity in the NMDA receptor system. To date, this relationship has not been 
examined in more clinically relevant models of persistent pain. Experiment 2 evaluated sex 
differences in the antihyperalgesic actions of select κ and mixed-action opioids in the 
capsaicin model of persistent pain.  Results of this experiment showed that while κ opioids 
were generally more potent in males, sex differences were not observed with the mixed-
action opioids that have activity at both the µ and κ receptors. In addition, κ opioids were 
more potent when administered locally, in the tail than systemically in both sexes, suggesting 
that the antihyperalgesia induced by local administration was mediated predominantly by 
activity at the site of inflammation (Ko et al. 1999).  The NMDA antagonist 
dextromethorphan attenuated the development of κ opioid antihyperalgesia equally in males 
and females. These findings contrast with those observed in acute pain models, where 
NMDA antagonists selectively block κ opioid-induced antinociception in males (Mogil et al. 
2003; Sternberg et al. 2004; Holtman and Wala 2006). Together these findings suggest that 
sex differences  NMDA system activity may be dependent upon the mechanisms underlying 
the different types of nociception. 
The purpose of Experiment 3 was to evaluate the role of the NMDA system in 
modulating sex differences in µ opioid-induced hyperalgesia in a model of persistent pain.  In 
acute pain models, NMDA antagonists have been shown to enhance the antinociceptive 
effects of the µ opioid morphine to a greater extent in males than females, but to date there 
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are no published reports of utilizing persistent pain models (Craft and Lee 2003; Grisel et al 
2005 but see Holtman et al. 2003 ). In Experiment 3, both acute (warm water tail-withdrawal 
and hot-plate) and persistent (capsaicin) pain models were utilized. In the capsaicin 
preparation, the NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of 
low to moderate doses of morphine in males, but had no effect in females. This result was 
seen across different pretreatment times for both morphine and dextromethorphan. In 
contrast, enhancement of morphine antinociception was observed in both males and females 
in the acute pain models, with the magnitude of this effect being greater in males. These 
findings demonstrate a sexually dimorphic interaction between NMDA antagonists and 
morphine in a persistent pain model that can be quantitatively distinguished from those 
observed in acute pain models. Taken together, the present series of studies highlight the 
importance of the type/duration of nociceptive stimulation when examining the role of 
diverse receptor systems in modulating sex-specific opioid activity. 
 
Pain models 
The pursuit of the mechanisms underlying the effectiveness of opioids can, in part, be 
traced to a seminal study by Lasagna and Beecher (1954) in which it was reported that 
standard doses of morphine failed to produce postsurgical pain relief in up to 35% of 
patients. While numerous factors have been found to contribute to these individual 
differences, sex is perhaps one of the most critical.  Interestingly, while this study of the 
effectiveness of morphine focused on postoperative pain that can persist for days to weeks, 
research on the influence of sex on opioid antinociception and the mechanisms underlying 
this relationship have focused almost exclusively on  models of acute, short acting pain. In 
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these models a noxious stimulus is applied to a portion of the body until a withdrawal 
response is observed (Fillingim and Ness, 2000; Mogil et al., 2000).  Results from 
experiments utilizing acute pain models have identified an extensive list of factors that 
influence sex differences in opioid sensitivity, including type of noxious stimulus, genetic 
factors and opioid efficacy. This line of research has also led to the demonstration of a 
limited role for pharmacokinetic factors, as systemic injections of morphine produce 
comparable blood and brain concentrations in male and female rats (Craft et al. 1996; Cicero 
et al. 1997). However, as clinical pain is more often persistent or chronic in nature a 
complete picture of sex difference in opioid sensitivity must encompass more models of long 
lasting pain. 
Persistent and acute models of pain vary greatly in many aspects, including the 
duration of nociception, activation of Aδ (phasic,acute) vs C (tonic, persistent) fibers, 
presence of inflammation, and tissue damage as well as the neurochemical substrates 
underlying these effects (Abbott et al 1981, Coderre and Melzack, 1992, Le Bars 2001). 
There is even evidence to suggest that pain models are sensitive to genetic factors, as rodent 
lines selected for high opioid sensitivity in a thermal nociceptive assay have been shown to 
be relatively insensitive to opioid antinociception in a persistent formalin assay (Mogil et al., 
1996).   
  Although opioids represent the typical treatment option for persistent pain in the 
clinical population, their effectiveness has been described as highly variable and often 
unpredictable (Przewlocki and Przewlocka, 2001). While some of this variability can be 
attributed to individual differences it is becoming increasing clear that different types or 
manifestations of persistent pain may be responsible for some of this variability. It is evident 
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from the limited research in this area that even at the level of persistent pain conditions, the 
type of persistent pain model utilized has a direct effect on the magnitude of sex differences 
in the response to opioid analgesics. For example, while the present set of studies found, a 
greater antihyperalgesic effect in males with κ opioids in the capsaicin preparation, Binder et 
al. (2000) reported that the peripherally active κ-opioid asimadoline was more effective in 
female rats at reducing Freunds-induced hyperalgesia. The involvement of the NMDA 
system in the persistent model is one critical factor that varies within persistent pain models. 
For example, experimental results show in the carrageenin model of acute inflammation, 
NMDA receptor antagonists reduced thermal hyperalgesia (Ren et al., 1992), while in a 
tissue injury model of post-operative pain,  NMDA receptor antagonists had no effect on 
mechanical hyperalgesia ( Zahn and Brennan, 1998). In the capsaicin preparation, the current 
and previous research (Sakurada et al., 1998) indicates the NMDA system does not influence 
the development and persistence of capsaicin-induced hyperalgesia. It is this characteristic 
which made the capsaicin preparation an excellent candidate for the examination of the 
relationship between sex differences, opioids and the NMDA system in persistent pain. As 
administration of the NMDA antagonist dextromethorphan alone had no effect on the 
development of the hyperalgesic response, any changes in the effects produced by 
opioids/dextromethorphan could be attributed to the direct effects of the NMDA system on 
opioid activity rather than changes in basal levels of nociception. 
In contrast, the NMDA system is more actively involved in other models of persistent 
pain. For example, the formalin model of pain nociception is distinguished  by 2 phases, the 
latter of which  is characterized ongoing stimulation of nociceptors, inflammation, as well as 
NMDA receptor activation (Fu et al., 2001). Similar to the formalin model, the nociceptive 
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response in the temporal summation model developed and tested in experiment 1 was 
determined to be NMDA dependent. In this temporal summation produced administration of 
various non-competitive NMDA antagonists decreased the level of temporal summation in 
both males and females at doses that failed to produce an antinociceptive effect in the acute 
tail-withdrawal procedure. This result was not surprising as temporal summation in humans 
is thought to mimic wind-up, a central mechanism implicated in the development of some 
chronic pain conditions (Dickenson and Sullivan 1987; Price et al. 1994; Arendt-Nielson et 
al. 1995; Graven-Neilson et al. 2000; Guirimand et al. 2000). It is important to note, 
however, that parametric analyses indicated nociceptive stimulus intensity greatly affected 
the degree to which NMDA antagonists reduced the temporal summation response, as greater 
attenuation was observed at the lower stimulus intensities.  It is thus possible that high 
nociceptive stimulus intensities may require activation of NMDA and non-NMDA systems in 
this model.   
Interestingly, in Experiments 2 and 3 it was the data obtained in the female animals 
that did not correspond to results reported in studies of sex differences in acute pain models. 
The NMDA antagonist dextromethorphan significantly attenuated the antihyperalgesic effect 
of the κ opioids U69,593, spiradoline and U50,488, and this effect was observed in both 
males and females. In contrast, NMDA antagonists have been shown to selectively 
antagonize the effects of κ opioids in male rats and mice using acute nociceptive procedures 
(e.g., Mogil et al. 2003; Holtman and Wala 2006, Kavaliers and Choleris 1997). Similarly, a 
dose-dependent enhancement of morphine antihyperalgesia was selectively obtained in 
males, whereas in acute models NMDA antagonists enhance the peak effect and duration of 
 97
morphine antinociception in both male and female animals (Grisel et al 2005, Nemmani et 
al., 2004, Craft and Lee, 2005).   
 
Implications and Future Directions  
Future investigation of the NMDA system modulation of sex differences should focus 
on the specific role of the numerous binding sites located on the NMDA receptor. The 
NMDA receptor is a large complex consisting of an ion channel and a number of binding 
sites that allow for various compounds to activate and regulate its activity (Mao et al., 1999). 
Antagonism of these specific receptor sites has become of interest partly due to their apparent 
ability to modulate opioid antinociception. Indeed, modulation has been achieved through 
competitive (i.e., LY-235959) and non-competitive channel blocking antagonism (i.e., 
dextromethorphan, MK-801) or actions at different sites such as the strychnine-insensitive 
glycine (i.e., (+)-HA-966) or polyamine site (i.e., ifenprodil) (Parsons, 2001). There is 
evidence that the antagonism of various binding sites on the NMDA receptor may have 
differential effects on opioid antinociception, with non-competitive channel blocking 
antagonists producing the most consistent enhancement of opioid antinociception (Trujillo 
and Akil, 1991, Pleasan et al., 1998; Redwine and Trujillo, 2003).  
It is extremely difficult at this time to begin to postulate the mechanisms underlying 
these diverse actions as the effects of NMDA antagonism varied across opioids (µ vs κ), 
sexes, and pain models. These diverse results do, however, rule out a number of simple 
explanations, such as estrous cycle, drug kinetics, drug pharmacokinetics (binding sites).  
While physiological studies have demonstrated an influence of gonadal hormones on the 
density of NMDA binding sites as well as NMDA antagonist induced c-fos expression   
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(Gazzaley et al. 1996) the current experiments did not systematically address the role of 
gonadal hormones in NMDA modulation of opioid antinociception/antihyperalgesia. It is 
possible that gonad hormone play an indirect role in this relationship. Based on the current 
findings, however, identification of the mechanisms underlying sex difference in NMDA 
modulation of opioid antinociception/antihyperalgesia requires extensive research examining  
different pain models that have distinct mechanisms underlying the development of pain. In 
this sense, animal research has followed a similar path as pain research in humans.  For a 
number of years the pervasive belief was indicated that opioids were more effective in 
females, as demonstrated in studies of oral surgery (Gordon et al 1995). However, more 
recently there many studies indicating the picture has changed considerably, as these 
differences have not been consistently observed. It appears that the type of pain experienced 
has an effect on the efficacy of the opioid in the general population as women were found to 
experience more severe postoperative pain and required a greater dose of morphine than men 
in the immediate postoperative period (Abrun et al., 2005). In acute laboratory pain 
conditions Fillingim et al (2005) found no sex difference in effectiveness of morphine 
analgesia (see also Zacny, 2001). In addition in conditions of chronic cancer pain no sex 
differences in morphine analgesia (Kaiki et al, 1983). 
Ultimately the goal of studying sex differences in antinociception is the identification 
of variables that can be used and manipulated in such a way as to increase the effectiveness 
of pain treatment in the general clinical population. Understanding the physiology of sex 
differences in pain and opioid effectiveness may also aid in understanding the origin of 
chronic pain disorders. While there is not a perfect relationship between findings in animal 
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studies and humans, it is the commonality of factors and the examination of differences that 
will ultimately aid in the treatment of various pain conditions.  
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